Encapsulated polynucleotide, and method for using the same

Lipid nanoparticles encapsulating synthetic RNA viral genomes address the limitations of replication-competent viruses by selectively targeting and lysing cancer cells, reducing tumor size and minimizing immune activation and collateral damage.

JP2024167285AInactive Publication Date: 2024-12-03ONCORUS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024143254
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-03
Filing Date
2024-08-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Clinical use of replication-competent viruses for cancer treatment is limited by innate immune responses, neutralizing antibodies, and collateral damage to non-diseased cells, making repeated systemic administrations ineffective for metastatic cancers.

Method used

Development of lipid nanoparticles encapsulating synthetic RNA viral genomes encoding oncolytic viruses, such as Seneca Valley virus or Coxsackie virus, which deliver recombinant RNA molecules capable of producing infectious virus particles that selectively target and lyse cancer cells while minimizing immune activation and extra-disease damage.

Benefits of technology

The encapsulated viral genomes effectively reduce tumor size and induce adaptive immune responses, achieving targeted cancer therapy with reduced systemic immune activation and collateral damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167285000042
    Figure 2024167285000042
  • Figure 2024167285000043
    Figure 2024167285000043
  • Figure 2024167285000044
    Figure 2024167285000044
Patent Text Reader

Abstract

To provide an encapsulated polynucleotide, and a method for using the polynucleotide.SOLUTION: The present invention relates to a recombinant RNA molecule encoding an oncolytic virus. The present invention further relates to use of recombinant RNA molecules and / or particles for encapsulation of recombinant RNA molecules and for treating and preventing cancer. In some embodiments, the present invention relates to a lipid nanoparticle (LNP) including a synthetic RNA virus genome encoding an oncolytic virus. In some embodiments, the oncolytic virus is a single-stranded RNA (ssRNA) virus.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 788,504, filed January 4, 2019, and U.S. Provisional Application No. 62 / 895,135, filed September 3, 2019, the contents of which are incorporated by reference herein in their entireties.

[0002] Description of electronically submitted text files The contents of the text file description submitted electronically herewith are incorporated herein by reference in their entirety. A computer-readable format copy of the sequence listing (file name: ONCR-015_01WO_SeqList_ST25.txt, date recorded: January 2, 2020, file size: 265 kilobytes).

[0003] The present disclosure relates generally to the fields of immunology, inflammation, and cancer therapy. More specifically, the present disclosure relates to particle-encapsulated viral genomes. The present disclosure further relates to the treatment and prevention of proliferative disorders, such as cancer. [Background technology]

[0004] Oncolytic viruses are replicable viruses with a lytic life cycle that can infect and lyse tumor cells. Direct tumor cell lysis not only leads to cell death, but also to the generation of adaptive immune responses directed to tumor antigens that are taken up and presented by local antigen-presenting cells. Thus, oncolytic viruses combat tumor cell growth through both direct cell lysis and the promotion of antigen-specific adaptive responses that can sustain antitumor responses after viral clearance.

[0005] However, the clinical use of replication-competent viruses presents several challenges. In general, viral exposure activates innate immune pathways, triggering a broad, non-specific inflammatory response. If the patient has not been previously exposed to the virus, this initial innate immune response may lead to the development of adaptive anti-viral responses and the production of neutralizing antibodies. If the patient has been previously exposed to the virus, pre-existing neutralizing anti-viral antibodies may prevent the desired lytic effect. In both cases, the presence of neutralizing antibodies not only prevents viral lysis of target cells, but also renders re-administration of viral therapy ineffective. These factors limit the use of viral therapy in the treatment of metastatic cancer, as the effectiveness of repeated systemic administrations required to treat such cancers is hindered by naturally occurring anti-viral responses. Even in the absence of such obstacles, subsequent viral replication in non-diseased cells may result in substantial non-disease collateral damage to surrounding cells and tissues.

[0006] There remains a long felt and unmet need in the art for compositions and methods relating to the therapeutic use of replication competent viruses. The present disclosure provides such compositions and methods. Summary of the Invention [Means for solving the problem]

[0007] In some embodiments, the present disclosure provides lipid nanoparticles (LNPs) comprising a synthetic RNA viral genome encoding an oncolytic virus. In some embodiments, the oncolytic virus is a single-stranded RNA (ssRNA) virus. In some embodiments, the oncolytic virus is a positive sense ((+)-sense) ssRNA virus. In some embodiments, the (+)-sense ssRNA virus is selected from those listed in Table 1. In some embodiments, the (+)-sense ssRNA virus is a picornavirus. In some embodiments, the picornavirus is a Seneca virus. Valley virus (SVV) or Coxsackie virus. In some embodiments, the SVV is SVV-A selected from wild type SVV-A (SEQ ID NO: 1), S177A-SVVA mutant (SEQ ID NO: 2), SVV-IR2 mutant (SEQ ID NO: 3), and SVV-IR2-S177A mutant (SEQ ID NO: 4). In some embodiments, the Coxsackie virus is selected from CVB3, CVA21, and CVA9. In some embodiments, the Coxsackie virus is a modified CVA21 virus comprising SEQ ID NO: 27.

[0008] In some embodiments, delivery of the LNPs to a cell results in the production of viral particles by the cell, which are infectious and lytic, hi some embodiments, the encoded oncolytic virus can reduce the size of a tumor that is remote from the site of administration of the LNPs to a subject.

[0009] In some embodiments, the synthetic RNA virus genome further comprises a heterologous polynucleotide encoding an exogenous payload protein. In some embodiments, the LNP further comprises a recombinant RNA molecule encoding an exogenous payload protein. In some embodiments, the exogenous payload protein is a fluorescent protein, an enzyme protein, a cytokine, a chemokine, an antigen binding molecule capable of binding to a cell surface receptor, or a ligand of a cell surface receptor. In some embodiments, the cytokine is selected from IL-12, GM-CSF, IL-18, IL-2, and IL-36γ. In some embodiments, the ligand of the cell surface receptor is Flt3 ligand or TNFSF14. In some embodiments, the chemokine is selected from CXCL10, CCL4, CCL21, and CCL5. In some embodiments, the antigen binding molecule is capable of binding to and inhibiting an immune checkpoint receptor. In some embodiments, the immune checkpoint receptor is PD-1. In some embodiments, the antigen binding molecule is capable of binding to a tumor antigen. In some embodiments, the antigen binding molecule is a bispecific T cell-engaged molecule (BiTE) or a bispecific light T cell-engaged molecule (LiTE). In some embodiments, the tumor antigen is DLL3 or EpCAM.

[0010] In some embodiments, the synthetic RNA virus genome and / or recombinant RNA molecule comprises a microRNA (miRNA) target sequence (miR-TS) cassette, the miR-TS cassette comprises one or more miRNA target sequences. In some embodiments, the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-124 target sequence, one or more copies of a miR-1 target sequence, and one or more copies of a miR-143 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-217 target sequence, one or more copies of a miR-137 target sequence, and one or more copies of a miR-126 target sequence.

[0011] In some embodiments, the LNP comprises a cationic lipid, one or more helper lipids, and a phospholipid-polymer complex. In some embodiments, the cationic lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly SS-18 / 4PE-13), COATSOME® SS-EC (formerly SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). In some embodiments, the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol.

[0012] In some embodiments, the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0013] In some embodiments, the phospholipid-polymer conjugate is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol (DPG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine). In some embodiments, the phospholipid-polymer conjugate is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PEG5K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K).

[0014] In some embodiments, the cationic lipid comprises COATSOME® SS-OC, the one or more helper lipids comprise cholesterol (Chol) and DSPC, and the phospholipid-polymer complex comprises DPG-PEG 2000. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5.

[0015] In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 49:11:38.5:1.5.

[0016] In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=45%-65%, B=5%-20%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=50%-60%, B=5%-15%, C=30%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=55%-60%, B=5%-15%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=55%-60%, B=5%-10%, C=30%-35%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 58:7:33.5:1.5.

[0017] In some embodiments, the LNP comprises a lipid formulation selected from Table 5.

[0018] In some embodiments, hyaluronan is conjugated to the surface of the LNP.

[0019] In some embodiments, the present disclosure provides a therapeutic composition comprising a plurality of lipid nanoparticles described herein. In some embodiments, the plurality of LNPs have an average size of about 50 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm. In some embodiments, the plurality of LNPs have an average size of about 50 nm to about 120 nm. In some embodiments, the plurality of LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm. In some embodiments, the plurality of LNPs have an average size of about 100 nm.

[0020] In some embodiments, the LNPs have an average zeta potential between about 40 mV to about -40 mV, about 20 mV to about -20 mV, about 10 mV to about -10 mV, about 5 mV to about -5 mV, or about 20 mV to about -40 mV. In some embodiments, the LNPs have an average zeta potential less than about -20 mV, less than about -30 mV, less than about 35 mV, or less than about -40 mV. In some embodiments, the LNPs have an average zeta potential between about -50 mV to about -20 mV, about -40 mV to about -20 mV, or about -30 mV to about -20 mV. In some embodiments, the LNPs have an average zeta potential of about -30 mV, about -31 mV, about -32 mV, about -33 mV, about -34 mV, about -35 mV, about -36 mV, about -37 mV, about -38 mV, about -39 mV, or about -40 mV.

[0021] In some embodiments, administration of the therapeutic composition to a subject results in delivery of the recombinant RNA polynucleotide to a target cell in the subject, where the recombinant RNA polynucleotide produces an infectious oncolytic virus capable of lysing the target cell in the subject, in some embodiments, the target cell is a cancerous cell.

[0022] In some embodiments, the compositions are formulated for intravenous or intratumoral delivery.

[0023] In some embodiments, the present disclosure provides a method of inhibiting the growth of a cancerous tumor in a subject in need thereof, comprising administering a therapeutic composition described herein to a subject in need thereof, wherein administering the composition inhibits the growth of the tumor. In some embodiments, the administration is intratumoral or intravenous. In some embodiments, the cancer is lung cancer, liver cancer, prostate cancer, bladder cancer, or melanoma.

[0024] In some embodiments, the disclosure provides a recombinant RNA molecule comprising a synthetic RNA virus genome encoding an oncolytic virus. In some embodiments, the encoded oncolytic virus is a single-stranded RNA (ssRNA) virus. In some embodiments, the ssRNA virus is a positive-sense ((+)-sense) or negative-sense ((-)-sense) ssRNA virus. In some embodiments, the (+)-sense ssRNA virus is a picornavirus. In some embodiments, the picornavirus is a Seneca Valley virus (SVV) or a Coxsackie virus. In some embodiments, the SVV is an SVV-A selected from wild-type SVV-A (SEQ ID NO: 1), an S177A-SVVA mutant (SEQ ID NO: 2), an SVV-IR2 mutant (SEQ ID NO: 3), or an SVV-IR2-S177A mutant (SEQ ID NO: 4). In some embodiments, the Coxsackie virus is selected from CVB3, CVA21, and CVA9. In some embodiments, the Coxsackie virus is a modified CVA21 virus comprising SEQ ID NO: 27.

[0025] In some embodiments, the recombinant RNA molecule further comprises a microRNA (miRNA) target sequence (miR-TS) cassette inserted into the polynucleotide sequence encoding the oncolytic virus, the miR-TS cassette comprises one or more miRNA target sequences, and the expression of one or more of the corresponding miRNAs in the cell inhibits the replication of the encoded virus in the cell. In some embodiments, the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126. In some embodiments, the miR-TS cassette comprises one or more copies of the miR-124 target sequence, one or more copies of the miR-1 target sequence, and one or more copies of the miR-143 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-217 target sequence, one or more copies of a miR-137 target sequence, and one or more copies of a miR-126 target sequence. In some embodiments, the one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more essential viral genes. In some embodiments, the one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more non-essential genes. In some embodiments, one or more miR-TS cassettes are integrated 5' or 3' of one or more essential viral genes.

[0026] In some embodiments, the recombinant RNA molecule can produce a replication-competent oncolytic virus when introduced into a cell by a non-viral delivery vehicle. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a mammalian cell present in a mammalian subject.

[0027] In some embodiments, the replication competent virus is selected from the group consisting of coxsackie virus, poliovirus, Seneca valley virus, lassa virus, murine leukemia virus, influenza A virus, influenza B virus, Newcastle disease virus, measles virus, sindbis virus, and maraba virus. In some embodiments, the replication competent virus is selected from those listed in Table 1.

[0028] In some embodiments, the recombinant RNA molecule is inserted into a nucleic acid vector. In some embodiments, the nucleic acid vector is a replicon.

[0029] In some embodiments, the synthetic RNA virus genome further comprises a heterologous polynucleotide encoding an exogenous payload protein. In some embodiments, the exogenous payload protein is a fluorescent protein, an enzyme protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand capable of binding to a cell surface receptor. In some embodiments, the cytokine is selected from IL-12, GM-CSF, IL-18, IL-2, and IL-36γ. In some embodiments, the ligand of the cell surface receptor is Flt3 ligand or TNFSF14. In some embodiments, the chemokine is selected from CXCL10, CCL4, CCL21, and CCL5. In some embodiments, the antigen-binding molecule can bind to and inhibit an immune checkpoint receptor. In some embodiments, the immune checkpoint receptor is PD-1. In some embodiments, the antigen-binding molecule can bind to a tumor antigen. In some embodiments, the antigen-binding molecule is a bispecific T cell-associated molecule (BiTE) or a bispecific light T cell-associated molecule (LiTE). In some embodiments, the tumor antigen is DLL3 or EpCAM.

[0030] In some embodiments, the disclosure provides a recombinant DNA molecule comprising, from 5' to 3', a promoter sequence, a 5' junction cleavage sequence, a polynucleotide sequence encoding a recombinant RNA molecule described herein, and a 3' junction cleavage sequence, in some embodiments, the promoter sequence is a T7 promoter sequence.

[0031] In some embodiments, the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a ribozyme sequence. In some embodiments, the 5' ribozyme sequence is a hammerhead ribozyme sequence and the 3' ribozyme sequence is a hepatitis delta virus ribozyme sequence. In some embodiments, the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a restriction enzyme recognition sequence. In some embodiments, the 5' ribozyme sequence is a hammerhead ribozyme sequence, a pistol ribozyme sequence, or a modified pistol ribozyme sequence. In some embodiments, the 3' restriction enzyme recognition sequence is a type IIS restriction enzyme recognition sequence. In some embodiments, the type IIS recognition sequence is a SapI recognition sequence. In some embodiments, the 5' junction cleavage sequence is an RNAseH primer binding sequence and the 3' junction cleavage sequence is a restriction enzyme recognition sequence.

[0032] In some embodiments, the disclosure provides a method of producing a recombinant RNA molecule described herein, comprising in vitro transcription of a DNA molecule described herein and purifying the resulting recombinant RNA molecule. In some embodiments, the recombinant RNA molecule comprises 5' and 3' ends that are native to the oncolytic virus encoded by the synthetic RNA virus genome.

[0033] In some embodiments, the present disclosure provides a composition comprising an effective amount of a recombinant RNA molecule described herein and a carrier, suitable for administration to a mammalian subject.

[0034] In some embodiments, the present disclosure provides a particle comprising a recombinant RNA molecule described herein. In some embodiments, the particle is biodegradable. In some embodiments, the particle is selected from the group consisting of a nanoparticle, an exosome, a liposome, and a lipoplex. In some embodiments, the exosome is a modified exosome derived from an intact exosome or an empty exosome. In some embodiments, the nanoparticle is a lipid nanoparticle (LNP) comprising a cationic lipid, one or more helper lipids, and a phospholipid-polymer complex.

[0035] In some embodiments, the cationic lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly SS-18 / 4PE-13), COATSOME® SS-EC (formerly SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). In some embodiments, the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol. In some embodiments, the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0036] In some embodiments, the phospholipid-polymer conjugate is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol (DPG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine).

[0037] In some embodiments, the phospholipid-polymer conjugate is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PEG5K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K).

[0038] In some embodiments, the cationic lipid comprises COATSOME® SS-OC, the one or more helper lipids comprise cholesterol (Chol) and DSPC, and the phospholipid-polymer complex comprises DPG-PEG 2000. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5.

[0039] In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 49:11:38.5:1.5. In some embodiments, the LNP comprises a lipid formulation selected from Table 5.

[0040] In some embodiments, the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). In some embodiments, the particle further comprises a phospholipid-polymer complex, and the phospholipid-polymer complex is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine).

[0041] In some embodiments, hyaluronan is conjugated to the surface of the LNP.

[0042] In some embodiments, the particle further comprises a second recombinant RNA molecule encoding a payload molecule, hi some embodiments, the second recombinant RNA molecule is a replicon.

[0043] In some embodiments, the present disclosure provides a therapeutic composition comprising a plurality of lipid nanoparticles described herein. In some embodiments, the plurality of LNPs have an average size of about 50 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm. In some embodiments, the plurality of LNPs have an average size of about 50 nm to about 120 nm. In some embodiments, the plurality of LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm. In some embodiments, the plurality of LNPs have an average size of about 100 nm.

[0044] In some embodiments, the LNPs have an average zeta potential between about 20 mV to about -20 mV, about 10 mV to about -10 mV, about 5 mV to about -5 mV, or about 20 mV to about -40 mV. In some embodiments, the LNPs have an average zeta potential less than about -20 mV, less than about -30 mV, less than about 35 mV, or less than about -40 mV. In some embodiments, the LNPs have an average zeta potential between about -50 mV to about -20 mV, about -40 mV to about -20 mV, or about -30 mV to about -20 mV. In some embodiments, the LNPs have an average zeta potential of about -30 mV, about -31 mV, about -32 mV, about -33 mV, about -34 mV, about -35 mV, about -36 mV, about -37 mV, about -38 mV, about -39 mV, or about -40 mV.

[0045] In some embodiments, delivery of the composition to a subject delivers the encapsulated recombinant RNA molecule to a target cell, where the encapsulated recombinant RNA molecule produces an infectious virus that can lyse the target cell. In some embodiments, the composition is formulated for intravenous or intratumoral delivery. In some embodiments, the target cell is a cancerous cell.

[0046] In some embodiments, the present disclosure provides inorganic particles comprising the recombinant polynucleotides described herein. In some embodiments, the inorganic particles are selected from the group consisting of gold nanoparticles (GNPs), gold nanorods (GNRs), magnetic nanoparticles (MNPs), magnetic nanotubes (MNTs), carbon nanohorns (CNHs), carbon fullerenes, carbon nanotubes (CNTs), calcium phosphate nanoparticles (CPNPs), mesoporous silica nanoparticles (MSNs), silica nanotubes (SNTs), or star-shaped hollow silica nanoparticles (SHNPs). In some embodiments, the inorganic particles further comprise a second recombinant RNA molecule encoding a payload molecule. In some embodiments, the second recombinant RNA molecule is a replicon.

[0047] In some embodiments, the disclosure provides compositions comprising inorganic particles as described herein, wherein the average diameter of the particles is less than about 500 nm, between about 50 nm and 500 nm, between about 250 nm and about 500 nm, or about 350 nm. In some embodiments, the disclosure provides compositions comprising inorganic particles as described herein, wherein the average diameter of the particles is between about 50 nm and 120 nm. In some embodiments, the average diameter of the particles is about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm. In some embodiments, the plurality of LNPs have an average size of about 100 nm.

[0048] In some embodiments, the present disclosure provides a method of killing a cancerous cell, comprising exposing the cancerous cell to a particle described herein, a recombinant RNA molecule described herein, or a composition thereof under conditions sufficient to intracellularly deliver the particle to the cancerous cell, and the replication-competent virus produced by the encapsulated polynucleotide results in the killing of the cancerous cell. In some embodiments, the replication-competent virus is not produced in a non-cancerous cell. In some embodiments, the method is performed in vivo, in vitro, or ex vivo.

[0049] In some embodiments, the present disclosure provides a method of treating cancer in a subject, comprising administering to a subject suffering from cancer an effective amount of a particle described herein, a recombinant RNA molecule described herein, or a composition thereof. In some embodiments, the particle or composition thereof is administered intravenously, intranasally, as an inhalant, or directly injected into a tumor. In some embodiments, the particle or composition thereof is administered repeatedly to the subject. In some embodiments, the subject is a mouse, a rat, a rabbit, a cat, a dog, a horse, a non-human primate, or a human.

[0050] In some embodiments, the cancer is selected from lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, bladder cancer, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), sarcoma, and marginal zone lymphoma (MZL). In some embodiments, the lung cancer is small cell lung cancer or non-small cell lung cancer. In some embodiments, the liver cancer is hepatocellular carcinoma (HCC). In some embodiments, the prostate cancer is neuroendocrine prostate cancer that appears during treatment. In some embodiments, the bladder cancer, pancreatic cancer, and gastric cancer are neuroendocrine subtypes. [Brief description of the drawings]

[0051] [Figure 1] A and B show the production of genome-containing RNA molecules and viral lysis of SVV. [Diagram 2] 1 shows successful RNA delivery and production of functional virus following treatment with SVV+ssRNA / LNP. [Figure 3-1] 1 shows that variation in lipid nanoparticle composition alters particle size and / or percentage of RNA capture. [Figure 3-2] 1 shows that variation in lipid nanoparticle composition alters particle size and / or percentage of RNA capture. [Figure 3-3] 1 shows that variation in lipid nanoparticle composition alters particle size and / or percentage of RNA capture. [Diagram 3-4] 1 shows that variation in lipid nanoparticle composition alters particle size and / or percentage of RNA capture. [Figure 4-1] Figure 1 shows the efficacy of SVV+ssRNA / LNP in the H1299 tumor model. Tumor volumes in H1299 tumor-bearing mice after intravenous administration of PBS or SVV+ssRNA / LNP (formulation no. 70001-5.C). [Figure 4-2]Figure 1 shows the efficacy of SVV+ssRNA / LNP in the H1299 tumor model. Figure 1 shows body weight measurements in H1299 tumor-bearing mice after intravenous treatment with PBS or SVV+ssRNA / LNP (formulation no. 70001-5.C). [Figure 5-1] 1 shows recovery of infectious SVV from tumors following intravenous administration of SVV+ssRNA / LNP. [Figure 5-2] 1 shows recovery of infectious SVV from tumors following intravenous administration of SVV+ssRNA / LNP. [Figure 6-1] Figure 1 shows the efficacy of SVV / LNP formulations 70009-1.C, 70009-2.C, and 70009-3.C in the H1299 tumor model. Figure 2 shows tumor volume in H1299 tumor-bearing mice after intravenous administration of PBS, SVV-Neg / LNP (formulation no. 70009-1.C), SVV / LNP (formulation no. 70009-2.C), or SVV-S177A / LNP (formulation no. 70009-3.C). [Figure 6-2] Figure 1 shows the efficacy of SVV / LNP formulations 70009-1.C, 70009-2.C, and 70009-3.C in the H1299 tumor model. Figure 2 shows body weight measurements in H1299 tumor-bearing mice after intravenous treatment with PBS, SVV-Neg / LNP (formulation no. 70009-1.C), SVV / LNP (formulation no. 70009-2.C), or SVV-S177A / LNP (formulation no. 70009-3.C). [Figure 6-3] Figure 6 shows the efficacy of SVV / LNP formulations 70009-1.C, 70009-2.C, and 70009-3.C in the H1299 tumor model. SVV replication in tumor (Figure 6C) or liver (Figure 6D) tissues isolated from H1299 tumor-bearing mice treated with PBS, SVV-Neg / LNP (formulation no. 70009-1.C), SVV / LNP (formulation no. 70009-2.C), or SVV-S177A / LNP (formulation no. 70009-3.C). [Figure 6-4]Figure 6 shows the efficacy of SVV / LNP formulations 70009-1.C, 70009-2.C, and 70009-3.C in the H1299 tumor model. SVV replication in tumor (Figure 6C) or liver (Figure 6D) tissues isolated from H1299 tumor-bearing mice treated with PBS, SVV-Neg / LNP (formulation no. 70009-1.C), SVV / LNP (formulation no. 70009-2.C), or SVV-S177A / LNP (formulation no. 70009-3.C). [Figure 7] 1 shows tumor volumes in H1299 tumor-bearing mice following intravenous administration of PBS or SVV-WT RNA lipid nanoparticles (formulation numbers 70053-1-1.C, 70053-2-2.C, 70059-1-3.C, and 70059-2-4.C). [Figure 8] Tumor volumes in H82 tumor-bearing mice are shown following intravenous administration of PBS or SVV-WT (formulation no. 70087-1.C) RNA-lipid nanoparticles, or following intratumoral administration of SVV-WT formulated with Lipofectamine. [Figure 9-1] Figure 1 shows the efficacy of SVV / LNP formulations 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C in the H1299 tumor model. Figure 2 shows tumor volume in H1299 tumor-bearing mice following intravenous administration of PBS or SVV-S177A RNA-lipid nanoparticles (formulation numbers 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C). [Figure 9-2] Figure 1 shows the efficacy of SVV / LNP formulations 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C in the H1299 tumor model. Figure 2 shows the weight measurements of H1299 tumor-bearing mice treated intravenously with PBS or SVV-S177A RNA-lipid nanoparticles (formulation numbers 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C). [Figure 9-3]Figure 1 shows the efficacy of SVV / LNP formulations 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C in the H1299 tumor model. Figure 2 shows serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in H1299 tumor-bearing mice treated intravenously with PBS or SVV-S177A RNA-lipid nanoparticles (formulation numbers 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C). [Figure 9-4] Figure 1 shows the efficacy of SVV / LNP formulations 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C in the H1299 tumor model. Figure 1 shows SVV replication in tumor tissue isolated from H1299 tumor-bearing mice treated intravenously with PBS or SVV-S177A RNA lipid nanoparticles (formulation numbers 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C). [Figure 10] 1 shows tumor volumes in H1299 tumor-bearing mice following intravenous administration of PBS or SVV-S177A RNA-lipid nanoparticles (formulation numbers 70087-1.C, 70087-2.C, 70087-3.C, and 70087-4.C). [Figure 11] 1 shows SVV replication in tumor tissue isolated from H1299 tumor-bearing mice treated intravenously with SVV-S177A RNA-lipid nanoparticles (formulation numbers 80010-1.C, 80010-2.C, 80010-3.C, 80010-4.C, and 80010-5.C). [Figure 12] 1 shows tumor volumes in H1299 tumor-bearing mice following intravenous administration of PBS or SVV-S177A RNA-lipid nanoparticles (formulation numbers 80033-1.C, 80033-2.C, and 80033-3.C). [Figure 13-1]1 shows the efficacy of SVV / LNP formulations 80059-1.C and 80059-2.C in the H446 tumor model. Tumor volumes in H446 tumor-bearing mice following intravenous administration of PBS, SVV-Neg LNPs (formulation no. 80059-1.C), or SVV-S177A LNPs (formulation no. 80059-2.C). [Figure 13-2] Figure 1 shows the efficacy of SVV / LNP formulations 80059-1.C and 80059-2.C in the H446 tumor model. Figure 1 shows the weight measurements of H446 tumor-bearing mice treated intravenously with PBS, SVV-Neg LNPs (formulation no. 80059-1.C), or SVV-S177A LNPs (formulation no. 80059-2.C). [Figure 13-3] Figure 1 shows the efficacy of SVV / LNP formulations 80059-1.C and 80059-2.C in the H446 tumor model. Figure 1 shows SVV replication in tumor tissue isolated from H446 tumor-bearing mice treated intravenously with PBS, SVV-Neg LNPs (formulation no. 80059-1.C), or SVV-S177A LNPs (formulation no. 80059-2.C). [Figure 14] 1 shows tumor volumes in H1299 tumor-bearing mice following intravenous administration of PBS, SVV-WT LNPs (formulation no. 80130-1.C), or SVV-IR2 LNPs (formulation no. 80130-2.C). [Figure 15] SVV replication in tumor tissue isolated from NIE-115 tumor-bearing mice treated intravenously with PBS, SVV-WT LNPs (formulation no. 80130-1.C), or SVV-IR2 LNPs (formulation no. 80130-2.C). [Figure 16] A and B show inhibition of SVV-mediated H446 cell lysis upon treatment with anti-SVV polyclonal antibodies. [Figure 17] Tumor volumes in H1299 tumor-bearing mice are shown following intravenous administration of PBS, SVV virus, or SVV-WT LNPs (formulation no. 80139-1.C) and intraperitoneal administration of rabbit serum or anti-SVV polyclonal antibody. [Figure 18]Tumor volumes in SK-MEL-28 tumor-bearing mice following intratumoral administration of PBS or CVA21-WT LNPs (formulation no. 70032-6C), or intravenous administration of CVA21-WT LNPs are shown. [Figure 19] FIG. 1 shows a schematic of an in vitro transcription approach to generate authentic 3′ ends for picornaviruses using a 3′ SapI restriction enzyme recognition site. [Figure 20] 1 shows an RNase H approach to generate authentic 5' ends for picornaviruses using a 5' DNA primer and RNase H enzyme. [Figure 21] Primer extension analysis of digested RNA with a 5' RNaseH primer binding site and a 3' SapI restriction site is shown. [Figure 22] 1 shows a ribozyme approach to generate authentic 5' ends for picornaviruses. [Diagram 23] 1 shows a hammerhead ribozyme for generating a distinct 5' end; 2 shows a structural model of a minimal hammerhead ribozyme (HHR) that anneals and cleaves at the 5' end of the arrow; 3 shows a structural model of a ribozyme with stabilized stem I (STBL) for cleavage of the 5' end of the arrow; [Figure 24] A and B show schematics of wild-type pistol ribozyme properties showing the pistol ribozyme for generation of separate 5' ends. Shown is the pistol ribozyme from P. Polymyxa with a tetraloop added to fuse the P3 strand modeled by mFOLD. The dashed boxes are regions that were mutated to retain the ribozyme folding in the context of the viral sequence. The "GUC" sequence shown in the dashed box was mutated to "UCA" to generate pistol 1, and the "GUC" sequence was mutated to "TTA" to generate pistol 2. [Diagram 25] We demonstrate that the Pistol 1 ribozyme effects complete cleavage during the in vitro transcription process. [Figure 26] 1 shows primer extension analysis by all ribozymes during the in vitro transcription process. [Figure 27]Detection of negative strand RNA is shown, confirming that the Pistol 1 ribozyme results in faster kick-off of SVV replication from an RNA template compared to constructs using a 5' hammerhead ribozyme. [Figure 28] Figure 1 shows increased in vivo efficacy of synthetic RNA SVV genomes generated with a 5' Pistol 1 ribozyme and a 3' SapI restriction site compared to constructs generated with a 5' hammerhead ribozyme. Tumor volumes in H1299 tumor-bearing mice following intravenous administration of PBS, SVV-HHR LNPs (formulation no. 80130-1.C), or SVV-PR LNPs (formulation no. 80130-3.C). [Figure 29] A and B show in vitro transcription of SVV RNA using modified ribonucleotides (Figure 29A) and viral replication of SVV RNA genomes containing modified nucleotides (Figure 29B). [Diagram 30] 4 shows viral replication (IC50 curves) of SVV and SVV encoding various payload molecules from the SVV viral genome. [Figure 31-1] Figure 1 shows the efficacy of SVV-RNA genome encoding IL-36γ in the H1299 tumor model.Tumor growth after treatment is shown. [Figure 31-2] Figure 1 shows the efficacy of SVV-RNA genome encoding IL-36γ in H1299 tumor model.Figure 2 shows IL-36γ expression in tumor tissue. [Diagram 32] A and B show the production of infectious CVA21 virus from an RNA polynucleotide. Effect of 5'UTR sequence on the production of infectious CVA21 from an RNA polynucleotide. Production of infectious CVA21 from an RNA polynucleotide containing the 5'UTR of SEQ ID NO:26. [Diagram 33] A schematic diagram of the LNP / SVV RNA composition and mode of action is shown. LNP / SVV-RNA is administered systemically to deliver the SVV-RNA genome to permissive tumor cells, which replicate and produce SVV-virions. SVV infection spreads to neighboring tumor cells, triggering tumor lysis and antiviral immune responses. [Diagram 34]Figure 1 shows the in vitro transcription process of SVV-RNA and Neg-RNA. Autocatalytic cleavage of SVV-RNA by 5' and 3' ribozymes (Rib) generates SVV-RNA with separate 5' and 3' ends required for replication. In contrast, the Neg-RNA construct lacks the ribozyme sequence and is incapable of replication and virion production. [Diagram 35] FIG. 1 shows a general schematic diagram of the use of junction cleavage sequences to remove non-viral RNA polynucleotides from a genomic transcript in order to maintain the native 5′ and 3′ separate ends of the virus. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0052] There is a need in the art for a viral therapy that is effective in the presence of neutralizing antibodies, can be administered repeatedly systemically, and has its replication restricted to diseased cells, thus maximizing therapeutic efficacy while minimizing collateral damage to normal non-cancerous cells. The present disclosure overcomes these obstacles and provides a replicable viral genome that can be encapsulated in a non-immunogenic particle, such as a lipid nanoparticle, a polymeric nanoparticle, or an exosome. In some embodiments, the particle further encapsulates a polynucleotide encoding a payload molecule. In some embodiments, the present disclosure provides a replicable viral genome and methods of use for the treatment and prevention of proliferative diseases and disorders (e.g., cancer). The present disclosure enables the systemic delivery of safe and effective recombinant polynucleotide vectors suitable for treating a wide range of proliferative disorders (e.g., cancer).

[0053] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents or portions of documents cited herein, including but not limited to patents, patent applications, articles, books, and treatises, are expressly incorporated herein by reference in their entirety for all purposes. In the event that one or more of the incorporated documents or portions of documents defines a term that contradicts the definition of that term in the application, the definition appearing in the application shall control. However, the mention of any references, papers, publications, patents, patent publications, and patent applications cited herein is not, and should not be taken as, any form of acknowledgment or suggestion that they constitute valid prior art or form part of the general knowledge in any country in the world.

[0054] A.Definition As used herein, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the stated range, and fractions thereof, where appropriate (such as tenths and hundredths of integers), unless otherwise indicated. The terms "a" and "an" as used herein should be understood to refer to "one or more" of the listed components, unless otherwise indicated. The use of alternatives (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms "include" and "comprise" are used synonymously. As used herein, "plurality" can refer to one or more components (e.g., one or more miRNA target sequences). In this application, the use of "or" means "and / or" unless otherwise indicated.

[0055] As used in this application, the terms "about" and "approximately" are used as equivalents. Any numbers with or without about / approximately used in this application are meant to cover any normal variations recognized by those of ordinary skill in the relevant art. In certain embodiments, the term "about" or "approximately" refers to a range of values ​​that is included in either direction (above or below) of the stated reference value, including 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less, unless otherwise stated or otherwise evident from the context (except where such numbers may exceed 100% of the possible values).

[0056] "Decrease" or "reduce" refers to a decrease or reduction in a particular value of at least 5%, e.g., 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, or 100%, as compared to a reference value. A decrease or reduction in a particular value can also be expressed as a fold change in the value as compared to the reference value, e.g., a decrease of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1000 or more times as compared to the reference value.

[0057] "Increase" refers to an increase in a particular value of at least 5%, e.g., 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, 100, 200, 300, 400, 500% or more compared to a reference value. An increase in a particular value can also be expressed as a fold change in value compared to a reference value, e.g., an increase of at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 500-fold, 1000-fold or more compared to the reference level.

[0058] The term "sequence identity" refers to the percentage of bases or amino acids between two polynucleotide or polypeptide sequences that are the same and in the same relative position. As such, one polynucleotide or polypeptide sequence has a certain percentage of sequence identity compared to another polynucleotide or polypeptide sequence. For sequence comparison, one sequence usually serves as a reference sequence to which test sequences are compared. The term "reference sequence" refers to the molecule to which test sequences are compared.

[0059] "Complementary" refers to the ability of pairing through base stacking and specific hydrogen bonding between two sequences containing natural or non-naturally occurring (e.g., modified as described above) bases (nucleotides) or their analogs. For example, if a base at a position of a nucleic acid can hydrogen bond with a base at a corresponding position of a target, then the bases are considered to be complementary to each other at that position. Nucleic acids can contain universal bases or inert abasic spacers that do not provide a positive or negative contribution to hydrogen bonding. Base pairs can include both standard Watson-Crick base pairs and non-Watson-Crick base pairs (e.g., wobble base pairs and Hoogsteen base pairs). In the case of complementary base pairs, it is understood that adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), and cytosine-type bases (C) are complementary to guanosine-type bases, with universal bases such as 3-nitropyrrole or 5-nitroindole hybridizing with and being considered complementary to any A, C, U, or T. Nichols et al., Nature, 1994; 369: 492-493, and Loakes et al., Nucleic Acids Res., 1994; 22: 4039-4043. Inosine (I) is also considered a universal base in the art and is considered complementary to any A, C, U, or T. See Watkins and SantaLucia, Nucl. Acids Research, 2005; 33(19): 6258-6267.

[0060] "Expression cassette" or "expression construct" refers to a polynucleotide sequence operably linked to a promoter. "Operably linked" refers to a juxtaposition in which the components so described are in a relationship permitting them to function in their intended manner. For example, a promoter is operably linked to a polynucleotide sequence if the promoter affects the transcription or expression of the polynucleotide sequence.

[0061] The term "subject" includes animals, such as, for example, mammals. In some embodiments, the mammal is a primate. In some embodiments, the mammal is a human. In some embodiments, the subject is a livestock animal, such as cattle, sheep, goats, dairy cows, pigs, or domesticated animals, such as dogs and cats. In some embodiments (e.g., particularly in research contexts), the subject is a rodent (e.g., mouse, rat, hamster), rabbit, primate, or pig, such as an inbred pig. The terms "subject" and "patient" are used interchangeably herein.

[0062] "Administering," as used herein, refers to the introduction of an agent or composition into a subject.

[0063] As used herein, "treatment" refers to the delivery of an agent or composition to a subject to affect physiological outcomes. In some embodiments, treatment refers to the treatment of disease in a mammal, e.g., a human, and includes (a) inhibiting disease, i.e., preventing the onset of disease or preventing disease progression, (b) relieving disease, i.e., causing regression of the disease state, and (c) curing disease.

[0064] The term "effective amount" refers to the minimum amount of an agent or composition required to produce a particular physiological effect (e.g., the amount required to increase, activate, and / or enhance a particular physiological effect). The effective amount of a particular agent can be expressed in a variety of ways based on the nature of the agent, such as mass / volume, number of cells / volume, particles / volume, (mass of agent) / (mass of subject), number of cells / (mass of subject), or particles / (mass of subject). The effective amount of a particular agent is expressed as half the maximum effective concentration (EC 50 ) and refers to the concentration of a drug that produces a particular magnitude of physiological response that is midway between a basal level and a maximum response level.

[0065] A "population" of cells refers to any number of cells greater than one, but preferably at least 1×10 3 cells, at least 1 x 10 4 cells, at least 1 x 10 5 cells, at least 1 x 10 6 cells, at least 1 x 10 7 cells, at least 1 x 10 8 cells, at least 1 x 10 9 cells, at least 1 x 10 10 A population of cells can refer to an in vitro population (e.g., a population of cells in culture) or an in vivo population (e.g., a population of cells present in a particular tissue).

[0066] "Effector function" refers to the functions of an immune cell involved in generating, maintaining, and / or enhancing an immune response directed against a target cell or target antigen.

[0067] The terms "microRNA," "miRNA," and "miR" are used interchangeably herein to refer to small, non-coding endogenous RNAs, approximately 21-25 nucleotides in length, that control gene expression by directing their target messenger RNAs (mRNAs) for degradation or translational repression.

[0068] As used herein, the term "composition" refers to a formulation of a recombinant RNA molecule or particle-encapsulated recombinant RNA molecule described herein that can be administered or delivered to a subject or a cell.

[0069] As used herein, the phrase "pharmacologically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the bounds of safe medical judgment, and commensurate with a reasonable benefit / risk ratio.

[0070] As used herein, a "pharmaceutically acceptable carrier, diluent, or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonicity agent, solvent, surface active agent, and / or emulsifier that is approved by the U.S. Food and Drug Administration as acceptable for use in humans and / or domestic animals.

[0071] The term "replicative viral genome" refers to a viral genome that encodes all of the viral genes necessary for viral replication and the production of infectious viral particles.

[0072] The term "oncolytic virus" refers to a virus that has been modified or naturally has a preferential infection of cancer cells.

[0073] The term "vector" is used herein to refer to a nucleic acid molecule capable of transporting or carrying another nucleic acid molecule.

[0074] General methods in molecular and cellular biochemistry are described in Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., Harbor Laboratory Press 2001), Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999), Protein Methods (Bollag et al., John Wiley & Sons 1996), Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999), Viral Vectors (Kaplift & Loewy eds., Academic Press 1995), Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997), and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998), the disclosures of which are incorporated herein by reference.

[0075] Synthetic RNA virus genome In some embodiments, the present disclosure provides a recombinant RNA molecule (e.g., RNA genome) that encodes an oncolytic virus. Such recombinant RNA molecules are referred to herein as "synthetic viral genomes" or "synthetic RNA viral genomes." In such embodiments, the synthetic RNA viral genome, when introduced into a cell by a non-viral delivery vehicle, can produce an infectious lytic virus and does not require additional exogenous genes or proteins present in the cell to replicate and produce infectious virus. Rather, endogenous translation mechanisms within the host cell mediate the expression of viral proteins from the synthetic RNA viral genome. The expressed viral proteins then mediate viral replication and assemble into infectious viral particles (which may include capsid proteins, envelope proteins, and / or membrane proteins) that include the RNA viral genome. Thus, the RNA polynucleotides described herein (i.e., synthetic RNA viral genomes), when introduced into a host cell, produce a virus that can infect another host cell. (See schematic diagram in Figure 33).

[0076] In some embodiments, the synthetic viral genome is provided as a recombinant ribonucleic acid (RNA) (i.e., a synthetic RNA viral genome). In some embodiments, the synthetic RNA viral genome comprises one or more nucleic acid analogs. Examples of nucleic acid analogs include 2'-O-methyl substituted RNA, 2'-O-methoxy-ethyl bases, 2'fluoro bases, locked nucleic acid (LNA), unlocked nucleic acid (UNA), bridged nucleic acid (BNA), morpholino, and peptide nucleic acid (PNA). In some embodiments, the synthetic RNA viral genome is a replicon, an RNA viral genome encoding a transgene, an mRNA molecule, or a circular RNA molecule (circRNA). In some embodiments, the synthetic RNA viral genome comprises a single-stranded RNA (ssRNA) viral genome. In some embodiments, the single-stranded genome can be a positive-sense or negative-sense genome.

[0077] In some embodiments, the recombinant RNA molecule is a circular RNA molecule (circRNA). CircRNA molecules lack the free ends required for exonuclease-mediated degradation, thus extending the half-life of the RNA molecule and allowing for more stable protein production over time (see, e.g., Wesselhoeft et al., Engineering circular RNA for potent and stable translation in eukaryotic cells. Nature Communications. (2018) 9:2629). To produce a functional RNA virus from a circRNA molecule, the circular construct needs to be "opened" once inside the cell so that a linear RNA genome with the appropriate 3' and 5' natural ends can be produced. Thus, in some embodiments, the recombinant RNA molecule encoding an oncolytic virus is provided as a circRNA molecule and further comprises one or more additional RNA sequences that facilitate linearization of the circRNA molecule in the cell. Examples of such additional RNA sequences include siRNA target sites, miRNA target sites, and guide RNA target sites. The corresponding siRNA, miRNA, or gRNA can be co-formulated with the circRNA molecule. Alternatively, miRNA target sites can be selected based on the expression of cognate miRNAs in target cells, such that cleavage of the circRNA molecule and initial expression of the encoded oncolytic virus is restricted to target cells expressing the specific miRNA.

[0078] The synthetic RNA viral genomes described herein encode oncolytic viruses. Examples of oncolytic viruses known in the art include, but are not limited to, picornaviruses (e.g., Coxsackie virus), polioviruses, measles viruses, vesicular stomatitis viruses, orthomyxoviruses, and maraba viruses. In some embodiments, the oncolytic virus encoded by the synthetic RNA viral genome is a virus of the family Picornaviridae, such as coxsackie virus, poliovirus (chimeric polioviruses such as PVS-RIPO and other chimeric picornaviruses), or Seneca valley virus, or any virus of chimeric origin from any of the many picornaviruses, a virus of the family Arenaviridae, such as lassa virus, a virus of the family Retroviridae, such as murine leukemia virus, a virus of the family Orthomyxoviridae, such as influenza A virus, a virus of the family Paramyxoviridae, such as Newcastle disease virus or measles virus, a virus of the family Reoviridae, such as mammalian orthoreovirus, a virus of the family Togaviridae, such as sindbis virus, or a virus of the family Rhabdoviridae, such as vesicular stomatitis virus (VSV) or maraba virus.

[0079] Positive-sense single-stranded RNA virus In some embodiments, the synthetic RNA virus genome described herein encodes a single-stranded RNA (ssRNA) virus genome. In some embodiments, the ssRNA virus is a positive-sense ssRNA (+sense ssRNA) virus. Exemplary +sense ssRNA viruses include members of the Picornaviridae family (e.g., including coxsackie virus, poliovirus, and Seneca Valley virus (SVV), SVV-A), the Coronaviridae family (e.g., alphacoronaviruses such as HCoV-229E and HCoV-NL63, betacoronaviruses such as HCoV-HKU1, HCoV-OC3, and MERS-CoV), the Retroviridae family (e.g., murine leukemia viruses), and the Togaviridae family (e.g., Sindbis virus). Additional exemplary genera and species of positive-sense ssRNA viruses are listed in Table 1 below. [Table 1]

[0080] In some embodiments, the recombinant RNA molecules described herein encode a picornavirus selected from Coxsackie virus, Poliovirus, and Seneca Valley virus (SVV). In some embodiments, the recombinant RNA molecules described herein encode a Coxsackie virus. In some aspects of this embodiment, the recombinant RNA molecule is a Coxsackie virus and comprises the 5'UTR sequence of SEQ ID NO: 26 (see, e.g., Brown et al., Complete Genomic Sequencing Shows that Polioviruses and Members of Human Enterovirus Species C Are Closely Related in the Noncapsid Coding Region. Journal of Virology, (2003) 77:16, p. 8973-8984. GenBank Accession No. AF546702). In such embodiments, the 5'UTR sequence of SEQ ID NO:26 unexpectedly increases production of functional Coxsackie virus compared to other previously described 5'UTR sequences (see, e.g., Newcombe et al., Cellular receptor interactions of C-cluster human group A coxsackieviruses Journal of General Virology (2003), 84, 3041-3050. GenBank Accession No. AF465515). In some aspects of this embodiment, the recombinant RNA molecule encodes a Coxsackie virus and comprises the sequence of SEQ ID NO:27.

[0081] In some embodiments, the synthetic RNA viral genome described herein encodes a Coxsackie virus. In some embodiments, the Coxsackie virus is selected from CVB3, CVA21, and CVA9. Exemplary Coxsackie virus nucleic acid sequences are provided in GenBank Reference No. M33854.1 (CVB3), GenBank Reference No. KT161266.1 (CVA21), and GenBank Reference No. D00627.1 (CVA9). In some embodiments, the synthetic RNA viral genome described herein encodes a modified CVA21 virus comprising SEQ ID NO:27. In some embodiments, the synthetic RNA viral genome described herein encodes a Seneca In some embodiments, the synthetic RNA virus genome described herein encodes a chimeric picornavirus (e.g., a virus that includes one portion, such as a capsid protein or IRES, from a first picornavirus, and another portion, such as a nonstructural gene, such as a protease or polymerase, from a second picornavirus). In some embodiments, the synthetic RNA virus genome described herein encodes a chimeric SVV. In some embodiments, the synthetic RNA virus genome described herein encodes a chimeric Coxsackie virus.

[0082] In some embodiments, the synthetic RNA virus genome comprises a microRNA (miRNA) target sequence (miR-TS) cassette, the miR-TS cassette comprises one or more miRNA target sequences, and the expression of one or more of the corresponding miRNAs in a cell inhibits the replication of the encoded oncolytic virus in the cell. In some embodiments, the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126. In some embodiments, the miR-TS cassette comprises one or more copies of the miR-124 target sequence, one or more copies of the miR-1 target sequence, and one or more copies of the miR-143 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence. In some embodiments, the miR-TS cassette comprises one or more copies of a miR-217 target sequence, one or more copies of a miR-137 target sequence, and one or more copies of a miR-126 target sequence.

[0083] In some embodiments, the synthetic RNA viral genome comprises one or more miR-TS cassettes integrated into the 5' untranslated region (UTR) or 3' UTR of one or more essential viral genes. In some embodiments, the synthetic RNA viral genome comprises one or more miR-TS cassettes integrated into the 5' untranslated region (UTR) or 3' UTR of one or more non-essential genes. In some embodiments, the synthetic RNA viral genome comprises one or more miR-TS cassettes integrated into the 5' or 3' of one or more essential viral genes.

[0084] In some embodiments, the synthetic RNA virus genome comprises a heterologous polynucleotide encoding a payload molecule. In such embodiments, the synthetic RNA virus genome drives the production of infectious oncolytic virus as well as the expression of the payload molecule. In such embodiments, the expression of the payload molecule can increase the therapeutic efficacy of the oncolytic virus. In some embodiments, the payload molecule is selected from IL-12 (e.g., an SVV genome encoding IL-12, such as SEQ ID NO: 8), GM-CSF (e.g., an SVV genome encoding GMCSF, such as SEQ ID NO: 7), CXCL10 (e.g., an SVV genome encoding CXCL10, such as SEQ ID NO: 10), IL-36γ (e.g., an SVV genome encoding IL-36γ, such as SEQ ID NO: 11), CCL21 (e.g., an SVV genome encoding CCL21), IL-18 (e.g., an SVV genome encoding IL-18), IL-2 (e.g., an SVV genome encoding IL-2), CCL4 (e.g., an SVV genome encoding CCL4), CCL5 (e.g., an SVV genome encoding CCL5), anti-CD3-anti-BiTE (e.g., an SVV genome encoding an anti-CD3-anti-FAP BiTE, such as SEQ ID NO: 9), an antigen binding molecule that binds DLL3, or an antigen binding molecule that binds EpCAM. See Examples 23 and 24. Further description of the types of payload molecules suitable for use in these embodiments is provided below.

[0085] Methods for Producing Recombinant RNA Virus Genomes In some embodiments, the synthetic RNA viral genomes described herein are produced in vitro using one or more vector templates that contain a polynucleotide encoding the synthetic RNA viral genome. The term "vector" is used herein to refer to a nucleic acid molecule that can transport, encode, or carry another nucleic acid molecule. The nucleic acid to be transported is usually inserted into the vector nucleic acid molecule. The vector may contain sequences that induce autonomous replication in the cell and / or may contain sequences sufficient to allow integration into the host cell DNA. In some embodiments, the recombinant RNA molecules described herein are produced using one or more viral vectors.

[0086] In some embodiments, the synthetic RNA viral genomes described herein are produced by introducing a polynucleotide encoding a recombinant RNA molecule into a suitable host cell in vitro (e.g., by transfection, transduction, electroporation, etc.). Suitable host cells include insect and mammalian cell lines. Culturing the host cell for an appropriate time allows for expression of the polynucleotide and production of the synthetic RNA viral genome. The synthetic RNA viral genome is then isolated from the host cell and formulated for therapeutic use (e.g., encapsulated into particles). A schematic diagram of the in vitro synthesis of an RNA viral genome with 3' and 5' ribozymes is shown in Figure 34. The same schematic diagram applies to the synthesis of an RNA viral genome using other combinations of junction cleavage sequences.

[0087] In some embodiments, recombinant RNA molecules comprising synthetic RNA virus genomes described herein require separate 5' and 3' ends that are native to the virus. RNA transcripts produced in vitro by T7 RNA polymerase or by mammalian RNA Pol II containing mammalian 5' and 3' UTRs do not contain the separate native ends required for the production of infectious RNA viruses. For example, T7 RNA polymerase requires a guanosine residue at the 5' end of the template polynucleotide to initiate transcription. However, SVV begins with a uridine residue at its 5' end. Thus, the T7 leader sequence required for in vitro transcription of SVV transcripts must be removed to generate the native 5'SVV end required for the production of functional infectious SVV. Thus, in some embodiments, polynucleotides suitable for use in the production of synthetic RNA virus genomes described herein require additional non-viral 5' and 3' sequences that allow for the generation of separate 5' and 3' ends that are native to the virus. Such sequences are referred to herein as junction cleavage sequences (JCS). Thus, in some embodiments, the junction cleavage sequence acts to cleave the T7 RNA polymerase or Pol II encoded RNA transcript at the junction of the viral RNA and mammalian mRNA sequence such that non-viral RNA polynucleotides are removed from the transcript to maintain separate endogenous 5' and 3' ends of the virus (see schematic diagram shown in Figure 35). In some embodiments, the junction cleavage sequence acts to generate appropriate ends during linearization of a DNA plasmid encoding a synthetic viral genome (e.g., using a 3' restriction enzyme recognition sequence to generate appropriate 3' ends upon linearization of the plasmid template and prior to in vitro transcription of the synthetic RNA genome).

[0088] The nature of the junction cleavage sequence and the removal of non-viral RNA from the viral genome transcript can be achieved by various methods. For example, in some embodiments, the junction cleavage sequence is the target of an RNA interference (RNAi) molecule. As used herein, "RNA interference molecule" refers to an RNA polynucleotide that mediates the degradation of a target mRNA sequence via an endogenous gene silencing pathway (e.g., Dicer and RNA-induced silencing complex (RISC)). Exemplary RNA interference agents include microRNA (miRNA), artificial miRNA (amiRNA), short hairpin RNA (shRNA), and small interfering RNA (siRNA). Additionally, any system for cleaving an RNA transcript at a specific site currently known in the art or defined in the future can be used to generate separate ends that are native to the virus.

[0089] In some embodiments, the RNAi molecule is a miRNA. miRNA refers to a naturally occurring small non-coding RNA molecule of about 18-25 nucleotides in length that is at least partially complementary to a target mRNA sequence. In animals, genes for miRNAs are transcribed into primary miRNAs (pri-miRNAs), which are double-stranded and form a stem-loop structure. Pri-miRNAs are then cleaved in the nucleus by the microprocessor complex, which includes class 2 RNase III, Drosha, and the microprocessor subunit, DCGR8, to form 70-100 nucleotide precursor miRNAs (pre-miRNAs). The pre-miRNAs form hairpin structures and are transported to the cytoplasm, where they are processed by the RNase III enzyme, Dicer, into miRNA duplexes of about 18-25 nucleotides. Although either strand of the duplex can function as a functional miRNA, typically one strand of the miRNA is degraded and only one strand is loaded onto Argonaute (AGO) nuclease to generate an effector RNA-induced silencing complex (RISC) in which the miRNA and its mRNA target interact (Wahid et al., 1803:11, 2010, 1231-1243). In some embodiments, the 5' and / or 3' junction cleavage sequence is a miRNA target sequence.

[0090] In some embodiments, the RNAi molecule is an artificial miRNA (amiRNA) derived from a synthetic miRNA embedded in a Pol II transcript. (See, e.g., Liu et al., Nucleic Acids Res (2008) 36:9; 2811-2834; Zeng et al., Molecular Cell (2002), 9; 1327-1333; Fellman et al., Cell Reports (2013) 5; 1704-1713.) In some embodiments, the 5' and / or 3' junction cleavage sequence is an amiRNA target sequence.

[0091] In some embodiments, the RNAi molecule is an siRNA molecule. siRNA generally refers to a double-stranded RNA molecule about 21-23 nucleotides in length. The double-stranded siRNA molecule is processed in the cytoplasm by association with a multiprotein complex called the RNA-induced silencing complex (RISC), during which the "passenger" sense strand is enzymatically cleaved from the double strand. The antisense "guide" strand contained in the activated RISC then guides the RISC to the corresponding mRNA by sequence complementarity, and AGO nuclease cleaves the target mRNA, causing specific gene silencing. In some embodiments, the siRNA molecule is derived from an shRNA molecule. shRNAs are single-stranded artificial RNA molecules about 50-70 nucleotides in length that form a stem-loop structure. Expression of the shRNA in cells is achieved by introducing a DNA polynucleotide encoding the shRNA by a plasmid or viral vector. The shRNA is then transcribed into a product that mimics the stem-loop structure of the pre-miRNA, and after export from the nucleus, the hairpin is processed by Dicer to form a double-stranded siRNA molecule, which is then processed by RISC to further mediate silencing of the target gene. In some embodiments, the 5' and / or 3' junction cleavage sequence is an siRNA target sequence.

[0092] In some embodiments, the junction cleavage sequence is a guide RNA (gRNA) target sequence. In such embodiments, the gRNA can be designed and introduced using a Cas endonuclease with RNase activity (e.g., Cas13) to mediate cleavage of the viral genome transcript at the precise junction site. In some embodiments, the 5' and / or 3' junction cleavage sequence is a gRNA target sequence.

[0093] In some embodiments, the junction cleavage sequence is a sequence encoding a pri-miRNA. When the polynucleotide encoding the viral genome (e.g., a recombinant RNA molecule) is transcribed, these sequences form a pri-miRNA stem-loop structure that is cleaved in the nucleus by Drosha, cleaving the transcript at the correct junction site. In some embodiments, the 5' and / or 3' junction cleavage sequence is a pri-mRNA target sequence.

[0094] In some embodiments, the junction cleavage sequence is a primer binding sequence that promotes cleavage by the endoribonuclease RNAse H. In such embodiments, a primer that anneals to the 5' and / or 3' junction cleavage sequence is added to an in vitro reaction along with the RNAse H enzyme. RNAse H specifically hydrolyzes the phosphodiester bond of RNA hybridized to DNA, thus allowing cleavage of the synthetic RNA genome intermediate at the precise junction cleavage sequence to produce the required 5' and 3' natural ends.

[0095] In some embodiments, the junction cleavage sequence is a restriction enzyme recognition site, resulting in the generation of separate ends of the viral transcript during linearization of plasmid-templated runoff RNA synthesis with T7 RNA polymerase. In some embodiments, the junction cleavage sequence is a type IIS restriction enzyme recognition site. Type IIS restriction enzymes comprise a specific group of enzymes that recognize asymmetric DNA sequences and cleave at a defined distance outside the recognition sequence, usually within 1-20 nucleotides. Exemplary type IIS restriction enzymes include AcuI, AlwI, BaeI, BbsI, BbvI, BccI, BceAI, BcgI, BciVI, BcoDI, BfuAI, BmrI, BpmI, BpuEI, BsaI, BsaXI, BseRI, BsgI, BsmAI, BsmBi, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BstI, CaspCI, EarI, EciI, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, MbolI, MlyI, MmeI, MnlL, NmeAIII, PleI, SapI, and SfaNI. The recognition sequences for these type IIS restriction enzymes are known in the art. New England at neb.com / tools-and-resources / selection-charts / type-iis-restriction-enzymes See the Biolabs website. In some embodiments, the junction cleavage sequence is a SapI restriction enzyme recognition site.

[0096] In some embodiments, the junction cleavage sequence is a sequence encoding a ribozyme that mediates the self-cleavage of the synthetic RNA genome intermediate to produce the naturally separate 5' and 3' ends required for the final synthetic viral RNA genome, and subsequently produces an infectious RNA virus. Exemplary ribozymes include hammerhead ribozymes (e.g., the hammerhead ribozyme shown in FIG. 23), Varkud satellite (VS) ribozyme, hairpin ribozyme, GIR1 branched ribozyme, glmS ribozyme, twister ribozyme, twister sister ribozyme, pistol ribozyme (e.g., pistol 1 and pistol 2 shown in FIG. 24), hatchet ribozyme, and hepatitis delta virus ribozyme. In some embodiments, the 5' and / or 3' junction cleavage sequence is a sequence encoding a ribozyme.

[0097] In some embodiments, the junction cleavage sequence is a sequence that encodes a ligand-induced self-cleaving ribozyme, referred to as an "aptazyme." An aptazyme is a ribozyme sequence that contains an incorporated aptamer domain that is specific for a ligand. Ligand binding to the aptamer domain triggers activation of the enzymatic activity of the ribozyme, thereby resulting in cleavage of the RNA transcript. Exemplary aptazymes include theophylline-dependent aptazymes (e.g., hammerhead ribozymes linked to a theophylline-dependent aptamer as described in Auslander et al. Mol, BioSyst. (2010) 6, 807-814), tetracycline-dependent aptazymes (e.g., Zhong et al., eLife 2016;5:e18858 DOI:10.7554 / eLife.18858; Win and Smolke, PNAS (2007) 104;14283-14288; Whittmann and Suess, Mol Biosyt (2011) 7;2419-2427; Xiao et al., Chem&Biol (2008) 15;125-1137; and Beilstein et al., ACS Syn Biol (2015) 4; 526-534), and guanine-dependent aptazymes (e.g., hammerhead ribozymes linked to guanine-dependent aptamers as described in Nomura et al., Chem Commun., (2012) 48(57); 7215-7217). In some embodiments, the 5' and / or 3' junction cleavage sequences are sequences encoding an aptazyme.

[0098] In some embodiments, the junction cleavage sequence is a target sequence of an RNAi molecule (e.g., an shRNA molecule, an miRNA molecule, an amiRNA molecule), or a gRNA molecule, or an RNAseH primer. In such embodiments, the junction cleavage sequence is at least partially complementary to the sequence of the RNAi molecule, the gRNA molecule, or the primer molecule. Methods of sequence alignment for comparison and determination of percent sequence identity and percent complementarity are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), by manual adjustment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology), by the method of Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402, and Altschul et al. This can be done using algorithms known in the art, including the BLAST and BLAST 2.0 algorithms described in (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.

[0099] In some embodiments, the 5' junction cleavage sequence and the 3' junction cleavage sequence are from the same group (e.g., both are RNAi target sequences, both are sequences encoding ribozymes, etc.). For example, in some embodiments, the junction cleavage sequence is an RNAi target sequence (e.g., an siRNA, shRNA, amiRNA, or miRNA target sequence) and is incorporated into the 5' and 3' ends of a polynucleotide encoding a viral genome (e.g., a recombinant RNA molecule). In such embodiments, the 5' and 3' RNAi target sequences can be the same (i.e., the same siRNA, amiRNA, or miRNA target) or different (i.e., the 5' sequence is the target of one siRNA, shmiRNA, or miRNA and the 3' sequence is the target of another siRNA, amiRNA, or miRNA). In some embodiments, the junction cleavage sequence is a guide RNA target sequence and is incorporated into the 5' and 3' ends of a polynucleotide encoding a viral genome (e.g., a recombinant RNA molecule). In such embodiments, the 5' and 3' gRNA target sequences can be the same (i.e., targets of the same gRNA) or different (i.e., the 5' sequence is a target of one gRNA and the 3' sequence is a target of another gRNA). In some embodiments, the junction cleavage sequence is a sequence encoding a pri-mRNA and is incorporated immediately at the 5' and 3' ends of a polynucleotide encoding a viral genome (e.g., a recombinant RNA molecule). In some embodiments, the junction cleavage sequence is a sequence encoding a ribozyme and is incorporated immediately at the 5' and 3' ends of a polynucleotide encoding a viral genome (e.g., a recombinant RNA molecule).

[0100] In some embodiments, the 5' junction cleavage sequence and the 3' junction cleavage sequence are from the same group but are different variants or types. For example, in some embodiments, the 5' and 3' junction cleavage sequence can be the target sequence of an RNAi molecule, the 5' junction cleavage sequence is a siRNA target sequence, and the 3' junction cleavage sequence is a miRNA target sequence (or vice versa). In some embodiments, the 5' and 3' junction cleavage sequence can be a sequence encoding a ribozyme, the 5' junction cleavage sequence is a sequence encoding a hammerhead ribozyme, and the 3' junction cleavage sequence is a sequence encoding a hepatitis delta virus ribozyme.

[0101] In some embodiments, the 5' junction cleavage sequence and the 3' junction cleavage sequence are different types. For example, in some embodiments, the 5' junction cleavage sequence is an RNAi target sequence (e.g., an siRNA, amiRNA, or miRNA target sequence), and the 3' junction cleavage sequence is a ribozyme sequence, an aptazyme sequence, a pri-miRNA sequence, or a gRNA target sequence. In some embodiments, the 5' junction cleavage sequence is a ribozyme sequence, and the 3' junction cleavage sequence is an RNAi target sequence (e.g., an siRNA, amiRNA, or miRNA target sequence), an aptazyme sequence, a sequence encoding a pri-miRNA, or a gRNA target sequence. In some embodiments, the 5' junction cleavage sequence is an aptazyme sequence, and the 3' junction cleavage sequence is an RNAi target sequence (e.g., an siRNA, amiRNA, or miRNA target sequence), a ribozyme sequence, a pri-miRNA sequence, or a gRNA target sequence. In some embodiments, the 5' junction cleavage sequence is a pri-miRNA sequence and the 3' junction cleavage sequence is an RNAi target sequence (e.g., an siRNA, amiRNA, or miRNA target sequence), a ribozyme sequence, an aptazyme sequence, or a gRNA target sequence. In some embodiments, the 5' junction cleavage sequence is a gRNA target sequence and the 3' junction cleavage sequence is an RNAi target sequence (e.g., an siRNA, amiRNA, or miRNA target sequence), a ribozyme sequence, a pri-miRNA sequence, or an aptazyme sequence.

[0102] Exemplary locations of junction cleavage sequences relative to the polynucleotide encoding the synthetic viral genome are shown in Tables A and B below. [Table A] [Table B-1] [Table B-2]

[0103] In some embodiments, the synthetic RNA viral genome described herein is produced in vitro by in vitro RNA transcription (see schematic diagram in FIG. 35). The synthetic RNA viral genome is then purified and formulated for therapeutic use (e.g., encapsulated in lipid nanoparticles). In some embodiments, the DNA polynucleotide comprises, 5' to 3', (i) a promoter sequence (e.g., T7 polymerase promoter), (ii) a 5' ribozyme sequence, (iii) a polynucleotide encoding a synthetic RNA viral genome, and (iv) a 3' ribozyme sequence. In some embodiments, the DNA polynucleotide comprises, 5' to 3', (i) a promoter sequence (e.g., T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., wild-type HHR or modified HHR such as those provided in FIG. 23), (iii) a polynucleotide encoding a synthetic RNA viral genome, and (iv) a 3' hepatitis delta virus ribozyme sequence.

[0104] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or modified HHR such as those provided in FIG. 23), (iii) a polynucleotide encoding a wild-type SVV-A genome, and (iv) a 3' hepatitis delta virus ribozyme sequence. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:12. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO:12. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR such as those provided in FIG. 23), (iii) a polynucleotide encoding the SVVA-S177A genome, and (iv) a 3' hepatitis delta virus ribozyme sequence. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:13. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO:13.

[0105] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as those provided in FIG. 23), (iii) a polynucleotide encoding the SVVA-IR2 genome, and (iv) a 3' hepatitis delta virus ribozyme sequence. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as those provided in FIG. 23), (iii) a polynucleotide encoding the SVVA-IR2-S77A genome, and (iv) a 3' hepatitis delta virus ribozyme sequence.

[0106] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' ribozyme sequence, (iii) a polynucleotide encoding a synthetic RNA viral genome, and (iv) a 3' restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as those provided in FIG. 23), (iii) a polynucleotide encoding a synthetic RNA viral genome, and (iv) a 3' SapI restriction enzyme recognition site.

[0107] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as provided in FIG. 23), (iii) a polynucleotide encoding a wild-type SVVA genome, and (iv) a 3' SapI restriction site. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 18. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO: 18. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as provided in FIG. 23), (iii) a polynucleotide encoding a SVVA-S177A genome, and (iv) a 3' SapI restriction site. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as those provided in FIG. 23), (iii) a polynucleotide encoding the SVVA-IR2 genome, and (iv) a 3' SapI restriction site. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' hammerhead ribozyme sequence (e.g., a wild-type HHR or a modified HHR, such as those provided in FIG. 23), (iii) a polynucleotide encoding the SVVA-S177A-IR2 genome, and (iv) a 3' SapI restriction site.

[0108] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' pistol-type ribozyme sequence (e.g., the pistol 1 or pistol 2 ribozyme sequence shown in FIG. 24), (iii) a polynucleotide encoding a synthetic RNA virus genome, and (iv) a 3' SapI restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' pistol 1 ribozyme sequence, (iii) a polynucleotide encoding a wild-type SVV genome, and (iv) a 3' SapI restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:14. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO:14. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' Pistol 2 ribozyme sequence, (iii) a polynucleotide encoding a wild-type SVV genome, and (iv) a 3' SapI restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 15. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO: 15.

[0109] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' Pistol 1 ribozyme sequence, (iii) a polynucleotide encoding the SVV-S177A genome, and (iv) a 3' SapI restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' Pistol 1 ribozyme sequence, (iii) a polynucleotide encoding the SVV-IR2 genome, and (iv) a 3' SapI restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:16. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO:16. In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' Pistol 1 ribozyme sequence, (iii) a polynucleotide encoding the SVV-IR2-S177A genome, and (iv) a 3' SapI restriction enzyme recognition site. In some embodiments, the DNA polynucleotide comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 17. In some embodiments, the DNA polynucleotide comprises or consists of SEQ ID NO: 17.

[0110] In some embodiments, the DNA polynucleotide comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' RNAseH primer binding site, (iii) a polynucleotide encoding a synthetic RNA viral genome, and (iv) a 3' restriction enzyme recognition site. In some embodiments, the DNA vector comprises, from 5' to 3', (i) a promoter sequence (e.g., a T7 polymerase promoter), (ii) a 5' RNAseH primer binding site, (iii) a polynucleotide encoding a synthetic RNA viral genome, and (iv) a 3' SapI restriction enzyme recognition site.

[0111] Particles containing synthetic RNA genomes In some embodiments, the synthetic RNA genomes described herein are encapsulated in a "particle." As used herein, a particle refers to a non-tissue derived composition of matter such as a liposome, lipoplex, nanoparticle, nanocapsule, microparticle, microsphere, lipid particle, exosome, vesicle, etc. In certain embodiments, the particle is non-proteinaceous and non-immunogenic. In such embodiments, encapsulation of the synthetic RNA genomes described herein allows for delivery of the viral genome without inducing a systemic anti-viral immune response and reduces the effect of neutralizing anti-viral antibodies. Additionally, encapsulation of the synthetic RNA genomes described herein protects the genome from degradation and facilitates introduction into target host cells. In some embodiments, the present disclosure provides a nanoparticle comprising the synthetic RNA genomes described herein. In some embodiments, the nanoparticle is a lipid nanoparticle. In some embodiments, the nanoparticle further comprises a second RNA molecule encoding a payload molecule.

[0112] In some embodiments, the particle is biodegradable in the subject.In such embodiments, multiple doses of the particle can be administered to the subject without the particle accumulating in the subject.Examples of suitable particles include polystyrene particles, poly(lactic-co-glycolic acid) PLGA particles, polypeptide-based cationic polymer particles, cyclodextrin particles, chitosan particles, lipid-based particles, poly(β-amino ester) particles, low molecular weight polyethyleneimine particles, polyphosphoester particles, disulfide cross-linked polymer particles, polyamidoamine particles, polyethyleneimine (PEI) particles, and PLURIONICS stabilized polypropylene sulfide particles.

[0113] In some embodiments, the polynucleotides described herein are encapsulated in inorganic particles. In some embodiments, the inorganic particles are gold nanoparticles (GNPs), gold nanorods (GNRs), magnetic nanoparticles (MNPs), magnetic nanotubes (MNTs), carbon nanohorns (CNHs), carbon fullerenes, carbon nanotubes (CNTs), calcium phosphate nanoparticles (CPNPs), mesoporous silica nanoparticles (MSNs), silica nanotubes (SNTs), or star-shaped hollow silica nanoparticles (SHNPs).

[0114] Preferably, the particles described herein are nanoscopic in size to enhance solubility, avoid complications that may be caused by aggregation in vivo, and promote pinocytosis. In some embodiments, the particles have an average diameter of less than about 1000 nm. In some embodiments, the particles have an average diameter of less than about 500 nm. In some embodiments, the particles have an average diameter of about 30 to about 100 nm, about 50 to about 100 nm, or about 75 to about 100 nm. In some embodiments, the particles have an average diameter of about 30 to about 75 nm, or about 30 to about 50 nm. In some embodiments, the particles have an average diameter of about 100 to about 500 nm. In some embodiments, the particles have an average diameter of about 200 to 400 nm. In some embodiments, the particles have an average size of about 350 nm. Exosomes

[0115] In some embodiments, the synthetic RNA genomes described herein are encapsulated in exosomes. Exosomes are small membrane vesicles of endocytic origin, where multivesicular bodies are released into the extracellular environment following fusion with a parent cell (e.g., the cell from which the exosomes are released, also referred to herein as a donor cell). The surface of the exosome comprises a lipid bilayer derived from the plasma membrane of the parent cell and may further comprise membrane proteins expressed on the parent cell surface. In some embodiments, the exosome may further comprise cytosol from the parent cell. Exosomes are produced by many different cell types, including epithelial cells, B and T lymphocytes, mast cells (MCs), dendritic cells (DCs), and have been identified in plasma, urine, bronchoalveolar lavage fluid, intestinal epithelial cells, and tumor tissue. There are no "exosome-specific" proteins, as the composition of exosomes depends on the parent cell type from which they are derived. However, many exosomes contain proteins associated with the intracellular vesicles from which they are derived (e.g., proteins associated with and / or expressed by endosomes and lysosomes). For example, exosomes can be enriched with antigen-presenting molecules such as major histocompatibility complexes I and II (MHC-I and MHC-II), tetraspanins (e.g., CD63), several heat shock proteins, cytoskeletal components such as actin and tubulin, proteins involved in intracellular membrane fusion, cell-cell interaction molecules (e.g., CD54), signaling proteins, and cytoplasmic enzymes.

[0116] Exosomes can mediate the transfer of cellular proteins from one cell (e.g., a parent cell) to a target or recipient cell by fusing the exosome membrane with the plasma membrane of the target cell. Thus, modifying the material encapsulated by exosomes provides a mechanism by which exogenous agents, such as the polynucleotides described herein, can be introduced into a target cell. Exosomes that have been modified to include one or more exogenous agents (e.g., the polynucleotides described herein) are referred to herein as "modified exosomes." In some embodiments, modified exosomes are produced by the introduction of an exogenous agent (e.g., the polynucleotides described herein) and introduced into a parent cell. In such embodiments, the exogenous nucleic acid is introduced into a parent exosome-producing cell such that the exogenous nucleic acid itself, or a transcript of the exogenous nucleic acid, is incorporated into the modified exosomes produced from the parent cell. The exogenous nucleic acid can be introduced into the parent cell by means known in the art, such as transduction, transfection, transformation, and / or microinjection of the exogenous nucleic acid.

[0117] In some embodiments, modified exosomes are produced by directly introducing a synthetic RNA genome described herein into an exosome. In some embodiments, a synthetic RNA genome described herein is introduced into an intact exosome. "Intact exosomes" refers to exosomes that contain proteins and / or genetic material derived from the parent cell from which they are produced. Methods for obtaining intact exosomes are known in the art (e.g., Alvarez-Erviti L. et al., Nat Biotechnol. 2011 Apr;29(4):34-5; Ohno S, et al., Mol Ther 2013 Jan;21(l):185-91, and EP Patent Publication No. 2010663).

[0118] In certain embodiments, the synthetic RNA genome is introduced into empty exosomes. "Empty exosomes" refers to exosomes that lack proteins and / or genetic material (e.g., DNA or RNA) derived from a parent cell. Methods for producing empty exosomes (e.g., lacking genetic material from a parent cell) are known in the art and include UV exposure, mutation / deletion of endogenous proteins that mediate the loading of nucleic acids into exosomes, and electroporation and chemical treatment to open pores in the exosome membrane so that endogenous genetic material exits the exosome through the open pores. In some embodiments, empty exosomes are produced by opening exosomes by treatment with an aqueous solution having a pH of about 9 to about 14 to obtain exosome membranes, removing intravesicular components (e.g., intravesicular proteins and / or nucleic acids), and reassembling the exosome membrane to form empty exosomes. In some embodiments, intravesicular components (e.g., intravesicular proteins and / or nucleic acids) are removed by ultracentrifugation or density gradient ultracentrifugation. In some embodiments, the membrane is reassembled by sonication, mechanical vibration, extrusion through a porous membrane, electric current, or a combination of one or more of these techniques. In certain embodiments, the membrane is reassembled by sonication.

[0119] In some embodiments, loading of intact or empty exosomes with the synthetic RNA genomes described herein to produce modified exosomes can be accomplished using conventional molecular biology techniques, such as in vitro transformation, transfection, and / or microinjection. In some embodiments, an exogenous agent (e.g., a polynucleotide described herein) is directly introduced into intact or empty exosomes by electroporation. In some embodiments, an exogenous agent (e.g., a polynucleotide described herein) is directly introduced into intact or empty exosomes by lipofection (e.g., transfection). Lipofection kits suitable for use in producing exosomes according to the present disclosure are known in the art and commercially available (e.g., FuGENE® HD Transfection Reagent from Roche and LIPOFECTAMINE™ 2000 from Invitrogen). In some embodiments, an exogenous agent (e.g., a polynucleotide described herein) is directly introduced into intact or empty exosomes by transformation using heat shock. In such embodiments, exosomes isolated from parent cells may be treated with Ca to permeabilize the exosome membrane. 2+ The exosomes are cooled in the presence of a divalent cation such as 1,2-dichlorophenyl ether (in CaCl2). The exosomes can then be incubated with exogenous nucleic acid and briefly heat shocked (e.g., incubated at 42°C for 30-120 seconds). In certain embodiments, loading of empty exosomes with an exogenous agent (e.g., a polynucleotide described herein) can be achieved by mixing or co-injecting the agent with the exosome membrane after removal of intravesicular components. Thus, modified exosomes reassembled from exosome membranes will incorporate the exogenous agent into the intravesicular space. Additional methods for producing exosome-encapsulated nucleic acids are known in the art (see, e.g., U.S. Pat. Nos. 9,889,210, 9,629,929, and 9,085,778, International PCT Publication Nos. WO2017 / 161010 and WO2018 / 039119).

[0120] Exosomes can be obtained from a number of different parental cells, including cell lines, bone marrow-derived cells, and cells derived from primary patient samples. Exosomes released from parental cells can be isolated from the supernatant of parental cell cultures by means known in the art. For example, the physical properties of exosomes can be exploited to separate exosomes from culture media or other sources, including separation based on charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc.), density (e.g., regular or gradient centrifugation), and Svedberg constant (e.g., sedimentation with or without external forces, etc.). Alternatively or additionally, isolation can be based on one or more biological properties, including methods that can use surface markers (e.g., precipitation, reversible binding to a solid phase, FACS separation, specific ligand binding, non-specific ligand binding, etc.). Analysis of exosome surface proteins can be determined by flow cytometry using fluorescently labeled antibodies against exosome-associated proteins such as CD63. Additional markers for characterizing exosomes are described in International PCT Publication No. WO2017 / 161010. In still further contemplated methods, exosomes can also be fused using chemical and / or physical methods, including PEG-induced fusion and / or ultrasonic fusion.

[0121] In some embodiments, size exclusion chromatography can be utilized to isolate exosomes. In some embodiments, exosomes can be further isolated after chromatographic separation by centrifugation techniques (of one or more chromatographic fractions), as is generally known in the art. In some embodiments, isolation of exosomes can involve a combination of methods, including, but not limited to, differential centrifugation as previously described (e.g., Raposo, G. et al., J. Exp. Med. 183, 1161-1172 (1996)), ultracentrifugation, size-based membrane filtration, concentration, and / or ratio zonal centrifugation.

[0122] In some embodiments, the exosome membrane comprises one or more of phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterol, and phosphatidylserine.Furthermore, the membrane can comprise one or more polypeptides and one or more polysaccharides, such as glycans.Exemplary exosome membrane compositions and methods for modifying the relative amounts of one or more membrane components are described in International PCT Publication No. WO2018 / 039119.

[0123] In some embodiments, the particles are exosomes and have a diameter of about 30 to about 100 nm, about 30 to about 200 nm, or about 30 to about 500 nm. In some embodiments, the particles are exosomes and have a diameter of about 10 nm to about 100 nm, about 20 nm to about 100 nm, about 30 nm to about 100 nm, about 40 nm to about 100 nm, about 50 nm to about 100 nm, about 60 nm to about 100 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 100 nm to about 200 nm, about 100 nm to about 150 nm, about 150 nm to about 200 nm, about 100 nm to about 250 nm, about 250 nm to about 500 nm, or about 10 nm to about 1000 nm. In some embodiments, the particles are exosomes and have a diameter of about 20 nm to 300 nm, about 40 nm to 200 nm, about 20 nm to 250 nm, about 30 nm to 150 nm, or about 30 nm to 100 nm.

[0124] Lipid Nanoparticles In certain embodiments, the synthetic RNA virus genome described herein is encapsulated in a lipid nanoparticle (LNP). In certain embodiments, the LNP comprises one or more lipids, such as triglycerides (e.g., tristearin), diglycerides (e.g., glycerol bahenate), monoglycerides (e.g., glycerol monostearate), fatty acids (e.g., stearic acid), steroids (e.g., cholesterol), and waxes (e.g., cetyl palmitate). In some embodiments, the LNP comprises one or more cationic lipids and one or more helper lipids. In some embodiments, the LNP comprises one or more cationic lipids, cholesterol, and one or more neutral lipids.

[0125] Cationic lipid refers to any of a number of lipid species that carry a net positive charge at a selected pH, such as physiological pH. Such lipids include, but are not limited to, 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), dioctadecyldimethylammonium (DODMA), distearyldimethylammonium (DSDMA), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC); N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylanhydride (DDA); Cationic lipids that have a positive charge below physiological pH include, but are not limited to, DODAP, DODMA, and DMDMA. In some embodiments, the cationic lipid is C. 18The cationic lipid comprises an alkyl chain, an ether bond between the head group and the alkyl chain, and 0-3 double bonds. Such lipids include, for example, DSDMA, DLinDMA, DLenDMA, and DODMA. The cationic lipid may comprise an ether bond and a pH-titratable head group. Such lipids include, for example, DODMA. Additional cationic lipids are described in U.S. Patent Nos. 7,745,651, 5,208,036, 5,264,618, 5,279,833, 5,283,185, 5,753,613, and 5,785,992, which are incorporated herein by reference.

[0126] In some embodiments, the cationic lipid comprises a protonizable tertiary amine head group. Such lipids are referred to herein as ionizable lipids. Ionizable lipids refer to lipid species that comprise an ionizable amine head group and typically comprise a pKa less than about 7. Thus, in an acidic pH environment, the ionizable amine head group becomes protonated such that the ionizable lipid preferentially interacts with negatively charged molecules (e.g., nucleic acids such as recombinant polynucleotides described herein), thus facilitating nanoparticle assembly and encapsulation. Thus, in some embodiments, the ionizable lipid can increase the loading of nucleic acids into lipid nanoparticles. In environments with a pH greater than about 7 (e.g., physiological [ka] In the present disclosure, the ionizable lipid comprises a neutral charge. When a particle containing the ionizable lipid is taken up into the low pH environment of an endosome (e.g., pH<7), the ionizable lipid is reprotonated and associates with the anionic endosomal membrane, facilitating the release of the contents encapsulated by the particle. In some embodiments, the LNP comprises an ionizable lipid, such as a 7.SS-cleavable, pH-responsive lipid mimetic (such as the COATSOME® SS series). Additional examples of cationic or ionizable lipids suitable for the formulations and methods of the present disclosure are described, for example, in WO2018089540A1, WO2017049245A2, US20150174261, US2014308304, US2015376115, WO201 / 199952, and WO2016 / 176330.

[0127] In some embodiments, the cationic lipid is an ionizable lipid selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly SS-18 / 4PE-13), COATSOME® SS-EC (formerly SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). In some embodiments, the cationic ionizable lipid is DLin-MC3-DMA (MC3). In some embodiments, the cationic ionizable lipid is COATSOME® SS-LC. In some embodiments, the cationic ionizable lipid is COATSOME® SS-EC. In some embodiments, the cationic ionizable lipid is COATSOME® SS-OC. In some embodiments, the cationic ionizable lipid is COATSOME® SS-OP. In some embodiments, the cationic ionizable lipid is L-319. In some embodiments, the cationic ionizable lipid is DOTAP.

[0128] In some embodiments, the LNPs comprise one or more non-cationic helper lipids (neutral lipids). Exemplary neutral helper lipids include (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine) (DLPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DiPPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diole ... glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), (1,2-dioleoyl-sn-glycero-3-phospho-(l'-rac-glycerol) (DOPG), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DO In some embodiments, the LNPs comprise DSPC, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), ceramide, sphingomyelin, and cholesterol. In some embodiments, the one or more helper lipids are selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol. In some embodiments, the LNPs comprise DSPC. In some embodiments, the LNPs comprise DOPC. In some embodiments, the LNPs comprise DLPE. In some embodiments, the LNPs comprise DOPE.

[0129] The use and inclusion of polyethylene glycol (PEG)-modified phospholipids and derivatized lipids, such as derivatized ceramides (PEG-CER), including N-octanoyl-sphingosine-l-[succinyl(methoxypolyethylene glycol)-2000] (C8 PEG-2000) in the liposomes and pharmaceutical compositions described herein is further contemplated, preferably in combination with one or more of the compounds and lipids disclosed herein.

[0130] In some embodiments, the lipid nanoparticles may further comprise one or more PEG-modified lipids comprising poly(ethylene glycol) chains up to 5 kDa in length covalently attached to one or more C6-C20 alkyl-containing lipids. In some embodiments, the LNPs further comprise 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine). In some embodiments, the LNPs further comprise a PEG-modified lipid selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PEG5K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K). In some embodiments, the LNPs further comprise DSPE-PEG5K. In some embodiments, the LNPs further comprise DPG-PEG2K. In some embodiments, the LNPs further comprise DSG-PEG2K. In some embodiments, the LNPs further comprise DMG-PEG2K. In some embodiments, the LNPs further comprise DSG-PEG5K. In some embodiments, the LNPs further comprise DMG-PEG5K. In some embodiments, the PEG-modified lipid is present at about 0.1% to about 1% of the total lipid content of the lipid nanoparticle. In some embodiments, the PEG-modified lipid is present at about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1.0%, about 1.5%, about 2.0%, about 2.5%, or about 3.0% of the total lipid content of the lipid nanoparticle.

[0131] In some embodiments, the lipid is modified with a cleavable PEG lipid. Examples of PEG derivatives with cleavable bonds include peptide bonds (Kulkarni et al. (2014). Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Mol Pharmaceutics 11:2390-9; Lin et al. (2015). Drug / dye-loaded, multifunctional PEG-chitosan-iron oxide nanocomposites for methotraxate synergistically self-targeted cancer therapy and dual model imaging. ACS Appl Mater Interfaces 7:11908-20.), disulfide bonds (Yan et al. (2014). A method to accelerate the gelation of disulfide-crosslinked hydrogels. Chin J Polym Sci 33: 118-27, Wu & Yan (2015). Copper nanopowder catalyzed cross-coupling of diaryl disulfides with aryl iodides in PEG-400. Synlett 26: 537-42), vinyl ether bond, hydrazone bond (Kelly et al. (2016). Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells. Org Biomol Chem 14:9278-86.), and ester bonds (Xu et al. (2008). Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release 130:238-45). See also Fang et al., (2017) Cleaveable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Delivery 24:2,22-32.

[0132] In some embodiments, the PEG lipid is an activated PEG lipid. Exemplary activated PEG lipids include PEG-NH2, PEG-MAL, PEG-NHS, and PEG-ALD. Such functionalized PEG lipids are useful for conjugating targeting moieties to lipid nanoparticles to direct the particles to specific target cells or tissues (e.g., by attachment of antigen-binding molecules, peptides, glycans, etc.).

[0133] In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is DOTAP. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is DLin-MC3-DMA (MC3). In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is COATSOME® SS-EC. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is COATSOME® SS-LC. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is COATSOME® SS-OC. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is COATSOME® SS-OP. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the cationic lipid is L-319.

[0134] In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the one or more helper lipids comprise cholesterol. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the one or more helper lipids comprise DLPE. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the one or more helper lipids comprise DSPC. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the one or more helper lipids comprise DOPE. In some embodiments, the LNPs comprise a cationic lipid and one or more helper lipids, where the one or more helper lipids comprise DOPC.

[0135] In some embodiments, the LNPs comprise a cationic lipid and at least two helper lipids, the cationic lipid is DOTAP, and the at least two helper lipids comprise cholesterol and DLPE. In some embodiments, the LNPs comprise a cationic lipid and at least two helper lipids, the cationic lipid is MC3, and the at least two helper lipids comprise cholesterol and DSPC. In some embodiments, the at least two helper lipids comprise cholesterol and DOPE. In some embodiments, the at least two helper lipids comprise cholesterol and DSPC. In some embodiments, the LNPs comprise a cationic lipid and at least three helper lipids, the cationic lipid is DOTAP, and the at least three helper lipids comprise cholesterol, DLPE, and DSPE. In some embodiments, the LNPs comprise a cationic lipid and at least three helper lipids, the cationic lipid is MC3, and the at least three helper lipids comprise cholesterol, DSPC, and DMG. In some embodiments, the at least three helper lipids comprise cholesterol, DOPE, and DSPE. In some embodiments, the at least three helper lipids include cholesterol, DSPC, and DMG. In some embodiments, the LNPs include DOTAP, cholesterol, and DLPE. In some embodiments, the LNPs include MC3, cholesterol, and DSPC. In some embodiments, the LNPs include DOTAP, cholesterol, and DOPE. In some embodiments, the LNPs include DOTAP, cholesterol, DLPE, and DSPE. In some embodiments, the LNPs include MC3, cholesterol, DSPC, and DMG. In some embodiments, the LNPs include DOTAP, cholesterol, DLPE, and DSPE-PEG. In some embodiments, the LNPs include MC3, cholesterol, DSPC, and DMG-PEG. In some embodiments, the LNPs include DOTAP, cholesterol, DOPE, and DSPE. In some embodiments, the LNPs include DOTAP, cholesterol, DOPE, and DSPE-PEG.In some embodiments, the LNP comprises SS-OC, DSPC, cholesterol, and DPG-PEG (eg, DPG-PEG2K).

[0136] In some embodiments, the LNPs comprise DOTAP, cholesterol (Chol), and DLPE, with a ratio of DOTAP:Chol:DLPE (as a percentage of total lipid content) of about 50:35:15. In some embodiments, the LNPs comprise DOTAP, cholesterol (Chol), and DLPE, with a ratio of DOTAP:Chol:DOPE (as a percentage of total lipid content) of about 50:35:15. In some embodiments, the LNPs comprise DOTAP, cholesterol (Chol), DLPE, DSPE-PEG, with a ratio of DOTP:Chol:DLPE (as a percentage of total lipid content) of about 50:35:15, and the particles comprise about 0.2% DSPE-PEG. In some embodiments, the LNPs comprise MC3, cholesterol (Chol), DSPC, and DMG-PEG, wherein the ratio of MC3:Chol:DSPC:DMG-PEG (as a percentage of the total lipid content) is about 49:38.5:11:1.5.

[0137] In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5.

[0138] In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:11:38.5:1.5.

[0139] In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=45%-65%, B=5%-20%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=50%-60%, B=5%-15%, C=30%-45%, and D=0%-3%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=55%-60%, B=5%-15%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=55%-60%, B=5%-10%, C=30%-35%, and D=1%-2%, and A+B+C+D=100%. In some embodiments, the LNPs comprise SS-OC, DSPC, cholesterol (Chol), and DPG-PEG2K, and the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 58:7:33.5:1.5.

[0140] In some embodiments, the nanoparticles are coated with glycosaminoglycans (GAGs) to modulate or enhance uptake of the nanoparticles by target cells (Figure 2). GAGs can be heparin / heparin sulfate, chondroitin sulfate / dermatan sulfate, keratan sulfate, or hyaluronic acid (HA). In certain embodiments, the surface of the nanoparticles is coated with HA to target the particles for uptake by tumor cells. In some embodiments, the lipid nanoparticles are coated with arginine-glycine-aspartic acid tripeptide (RGD peptide) (see Ruoslahti, Advanced Materials, 24, 2012, 3747-3756, and Bellis et al., Biomaterials, 32(18), 2011, 4205-4210).

[0141] In some embodiments, the LNPs have an average size of about 50 nm to about 500 nm. For example, in some embodiments, the LNPs have an average size of about 50 nm to about 200 nm, about 100 nm to about 200 nm, about 150 nm to about 200 nm, about 50 nm to about 150 nm, about 100 nm to about 150 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm. In some embodiments, the LNPs have an average size of about 50 nm to about 120 nm. In some embodiments, the LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm. In some embodiments, the LNPs have an average size of about 100 nm.

[0142] In some embodiments, the LNPs have a neutral charge (e.g., an average zeta potential of about 0 mV to about 1 mV). In some embodiments, the LNPs have an average zeta potential of about 40 mV to about -40 mV. In some embodiments, the LNPs have an average zeta potential of about 40 mV to about 0 mV. In some embodiments, the LNPs have an average zeta potential of about 35 mV to about 0 mV, about 30 mV to about 0 mV, about 25 mV to about 0 mV, about 20 mV to about 0 mV, about 15 mV to about 0 mV, about 10 mV to about 0 mV, or between about 5 mV to about 0 mV. In some embodiments, the LNPs have an average zeta potential of about 20 mV to about -40 mV. In some embodiments, the LNPs have an average zeta potential of about 20 mV to about -20 mV. In some embodiments, the LNPs have an average zeta potential of about 10 mV to about -20 mV. In some embodiments, the LNPs have an average zeta potential of about 10 mV to about -10 mV. In some embodiments, the LNPs have an average zeta potential of about 10 mV, about 9 mV, about 8 mV, about 7 mV, about 6 mV, about 5 mV, about 4 mV, about 3 mV, about 2 mV, about 1 mV, about 0 mV, about -1 mV, about -2 mV, about -3 mV, about -4 mV, about -5 mV, about -6 mV, about -7 mV, about -8 mV, about -9 mV, about -10 mV.

[0143] In some embodiments, the LNPs have an average zeta potential of about 0 mV to about -20 mV. In some embodiments, the LNPs have an average zeta potential of less than about -20 mV. For example, in some embodiments, the LNPs have an average zeta potential of less than about -30 mV, less than about 35 mV, or less than about -40 mV. In some embodiments, the LNPs have an average zeta potential of between about -50 mV to about -20 mV, about -40 mV to about -20 mV, or about -30 mV to about -20 mV. In some embodiments, the LNP is at about 0 mV, about -1 mV, about -2 mV, about -3 mV, about -4 mV, about -5 mV, about -6 mV, about -7 mV, about -8 mV, about -9 mV, about -10 mV, about -11 mV, about -12 mV, about -13 mV, about -14 mV, about -15 mV, about -16 mV, about -17 mV, about -18 mV, about -19 mV, about -20 mV, about The average zeta potential is about -21 mV, about -22 mV, about -23 mV, about -24 mV, about -25 mV, about -26 mV, about -27 mV, about -28 mV, about -29 mV, about -30 mV, about -31 mV, about -32 mV, about -33 mV, about -34 mV, about -35 mV, about -36 mV, about -37 mV, about -38 mV, about -39 mV, or about -40 mV.

[0144] In some embodiments, the lipid nanoparticles comprise a recombinant nucleic acid molecule as described herein and comprise a lipid (L) to nucleic acid (N) ratio of about 3:1 (L:N). In some embodiments, the lipid nanoparticles comprise a recombinant nucleic acid molecule as described herein and comprise a L:N ratio of about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1. In some embodiments, the lipid nanoparticles comprise a recombinant nucleic acid molecule as described herein and comprise a lipid (L) to nucleic acid (N) ratio of about 7:1 (L:N). In some embodiments, the lipid nanoparticles comprise a recombinant nucleic acid molecule as described herein and comprise a L:N ratio of about 4.5:1, about 4.6:1, about 4.7:1, about 4.8:1, about 4.9:1, about 5:1, about 5.1:1, about 5.2:1, about 5.3:1, about 5.4:1, or about 5.5:1. In some embodiments, the lipid nanoparticles comprise a recombinant nucleic acid molecule described herein and have an L:N ratio of about 6.5:1, 6.6:1, 6.7:1, 6.8:1, 6.9:1, 7:1, 7.1:1, 7.2:1, 7.3:1, 7.4:1, and 7.5:1.

[0145] In some embodiments, the LNP comprises a lipid formulation selected from one of the formulations listed in Table 5.

[0146] In some embodiments, the LNPs comprise a synthetic RNA virus genome that encodes an oncolytic virus, and the encoded oncolytic virus can reduce the size of a tumor that is remote from the site of LNP administration to a subject. For example, as demonstrated in the examples provided herein, intravenous administration of the LNPs described herein results in viral replication in tumor tissue and reduced tumor size. These data indicate that the LNPs of the present disclosure can localize to tumors or cancerous tissues that are remote from the site of LNP administration. Such an effect allows the use of the LNP-encapsulated oncolytic viruses described herein in the treatment of tumors that are not readily accessible and therefore not suitable for intratumoral delivery of therapy.

[0147] Payload molecules In some embodiments, the particle comprises a synthetic RNA virus genome and further comprises a recombinant RNA polynucleotide encoding a payload molecule. In some embodiments, the particle is a lipid nanoparticle and comprises a synthetic RNA virus genome and further comprises a recombinant RNA polynucleotide encoding a payload molecule. In some embodiments, one or more miRNA target sequences are incorporated into the 3' or 5' UTR of the RNA polynucleotide encoding the payload molecule. In some embodiments, one or more miRNA target sequences are inserted into the polynucleotide encoding the payload molecule. In such embodiments, translation and subsequent expression of the payload does not occur or is substantially reduced in cells in which the corresponding miRNA is expressed. In some embodiments, the recombinant RNA polynucleotide encoding the payload molecule is a replicon.

[0148] In some embodiments, the payload is a cytotoxic peptide. As used herein, "cytotoxic peptide" refers to a protein that can induce cell death when expressed in a host cell and / or cell death of neighboring cells when secreted by a host cell. In some embodiments, the cytotoxic peptide is a caspase, p53, diphtheria toxin (DT), Pseudomonas exotoxin A (PEA), type I ribozyme inactivating protein (RIP) (e.g., saporin and gelonin), type II RIP (e.g., ricin), Shiga-like toxin 1 (Slt1), photosensitive reactive oxygen species (e.g., killer red). In certain embodiments, the cytotoxic peptide is encoded by a suicide gene that causes cell death via apoptosis, such as a caspase gene.

[0149] In some embodiments, the payload is an immunomodulatory peptide. As used herein, an "immunomodulatory peptide" is a peptide that can modulate (e.g., activate or inhibit) a particular immune receptor and / or pathway. In some embodiments, the immunomodulatory peptide can act on any mammalian cell, including immune cells, tissue cells, and stromal cells. In preferred embodiments, the immunomodulatory peptide acts on immune cells such as T cells, NK cells, NKT T cells, B cells, dendritic cells, macrophages, basophils, mast cells, or eosinophils. Exemplary immunomodulatory peptides include antigen-binding molecules such as antibodies or antigen-binding fragments thereof, cytokines, chemokines, soluble receptors, cell surface receptor ligands, bipartite peptides, and enzymes.

[0150] In some embodiments, the payload is a cytokine, such as IL-1, IL-12, IL-18, IL-36γ, TNFα, IFNα, IFNβ, IFNγ, or TNFSF14. In some embodiments, the payload is a chemokine, such as CXCL10, CXCL9, CCL21, CCL4, or CCL5. In some embodiments, the payload is a ligand of a cell surface receptor, such as an NKG2D ligand, a neuropilin ligand, an Flt3 ligand, a CD47 ligand (e.g., SIRP1α). In some embodiments, the payload is a soluble receptor, such as a soluble cytokine receptor (e.g., IL-13R, TGFβR1, TGFβR2, IL-35R, IL-15R, IL-2R, IL-12R, and an interferon receptor) or a soluble innate immune receptor (e.g., Toll-like receptor, complement receptor, etc.). In some embodiments, the payload is a dominant agonist mutant of a protein involved in intracellular RNA and / or DNA sensing (e.g., a dominant agonist mutant of STING, RIG-1, or MDA-5).

[0151] In some embodiments, the payload is an antigen-binding molecule, such as an antibody or an antigen-binding fragment thereof (e.g., single chain variable fragment (scFv), F(ab), etc.). In some embodiments, the antigen-binding molecule specifically binds to a cell surface receptor, such as an immune checkpoint receptor (e.g., PD-1, PD-L1, and CTLA4) or additional cell surface receptors involved in cell growth and activation (e.g., OX40, CD200R, CD47, CSF1R, 41BB, CD40, and NKG2D).

[0152] In some embodiments, the payload molecule is a scorpion polypeptide, such as chlorotoxin, BmKn-2, neopragin 1, neopragin 2, and mauriporin. In some embodiments, the payload molecule is a snake polypeptide, such as contortrostatin, apoxin-I, bothropstoxin-I, BJcuL, OHAP-1, rhodostomin, drCT-I, CTX-III, B1L, and ACTX-6. In some embodiments, the payload molecule is a spider polypeptide, such as latarcin and hyaluronidase. In some embodiments, the payload molecule is a bee polypeptide, such as melittin and apamin. In some embodiments, the payload molecule is a frog polypeptide, such as PsT-1, PdT-1, and PdT-2.

[0153] In some embodiments, the payload is an enzyme. In some embodiments, the enzyme can modulate the tumor microenvironment by modifying the extracellular matrix. In such embodiments, the enzyme can include, but is not limited to, matrix metalloproteases (e.g., MMP9), collagenase, hyaluronidase, gelatinase, or elastase. In some embodiments, the enzyme is part of a gene-directed enzyme prodrug therapy (GDEPT) system, such as herpes simplex virus thymidine kinase, cytosine deaminase, nitroreductase, carboxypeptidase G2, purine nucleoside phosphorylase, or cytochrome P450. In some embodiments, the enzyme can induce or activate a cell death pathway in a target cell (e.g., caspase). In some embodiments, the enzyme can degrade an extracellular metabolite or message (e.g., arginase or 15-hydroxyprostaglandin dehydrogenase).

[0154] In some embodiments, the payload molecule is a bipartite peptide. As used herein, a "bipartite peptide" refers to a multimeric protein consisting of a first domain capable of binding to a cell surface antigen expressed on a non-cancerous effector cell and a second domain capable of binding to a cell surface antigen expressed by a target cell (e.g., a cancerous cell, a tumor cell, or a different type of effector cell). In some embodiments, the individual polypeptide domains of the bipartite polypeptide may comprise an antibody or a binding fragment thereof (e.g., a single chain variable fragment (scFv) or F(ab)), a nanobody, a diabody, a flexibody, a DOCK-AND-LOCK™ antibody, or a monoclonal anti-idiotypic antibody (mAb2). In some embodiments, the structure of the bipartite polypeptide may be a dual variable domain antibody (DVD-Ig™), a Tandab™, a bispecific T-cell engagement (BiTE™), a DuoBody™, or a dual affinity retargeting (DART) polypeptide. In some embodiments, the bipartite polypeptide is a BiTE and comprises a domain that specifically binds to an antigen shown in Table 3 and / or Table 4. Exemplary BiTEs are shown in Table 2 below. [Table 2]

[0155] In some embodiments, the cell surface antigen expressed on the effector cell is selected from Table 3 below. In some embodiments, the cell surface antigen expressed on the tumor cell or effector cell is selected from Table 4 below. In some embodiments, the cell surface antigen expressed on the tumor cell is a tumor antigen. In some embodiments, the tumor antigen is selected from CD19, EpCAM, CEA, PSMA, CD33, EGFR, Her2, EphA2, MCSP, ADAM17, PSCA, 17-A1, NKGD2 ligand, CSF1R, FAP, GD2, DLL3, or neuropilin. In some embodiments, the tumor antigen is selected from those listed in Table 4. [Table 3] [Table 4-1] [Table 4-2]

[0156] Therapeutic Compositions and Methods of Use One aspect of the present disclosure relates to therapeutic compositions comprising the recombinant RNA molecules described herein, or particles comprising the recombinant RNA molecules described herein, and methods of treating cancer. The compositions described herein can be formulated in any manner suitable for the desired delivery route. Typically, the formulation includes any physiologically acceptable composition, including derivatives or prodrugs, solvates, stereoisomers, racemates, or tautomers thereof, and any pharmaceutically acceptable carriers, diluents, and / or excipients.

[0157] As used herein, a "pharmaceutically acceptable carrier, diluent, or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonicity agent, solvent, surface active agent, and / or emulsifier that is approved by the U.S. Food and Drug Administration as acceptable for use in humans and / or domestic animals. Exemplary pharma- ceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffin, silicones, bentonite, silicic acid, zinc oxide; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffers; and any other compatible substance utilized in pharmaceutical formulations.

[0158] "Pharmaceutically acceptable salts" includes both acid addition salts and base addition salts. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of a protein) including, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glyceric ... It is formed from organic acids such as glycerol, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases, such as, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like.Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, naturally occurring substituted amines such as polyamine resins, cyclic amines, and substituted amines including basic ion exchange resins. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0159] The present disclosure provides a method of killing a cancerous or target cell, comprising exposing the cell to an RNA polynucleotide or particle described herein, or a composition thereof, under conditions sufficient for intracellular delivery of the composition to the cancerous cell. As used herein, "cancerous cell" or "target cell" refers to a mammalian cell selected for treatment or administration with a polynucleotide or particle described herein, or a composition thereof, as described herein. As used herein, "killing a cancerous cell" refers to, among other things, the death of a cancerous cell by apoptosis or necrosis. The killing of a cancerous cell can be determined by methods known in the art, including, but not limited to, tumor size measurement, cell count, and flow cytometry for detection of cell death markers such as Annexin V and uptake of propidium iodide.

[0160] The present disclosure further provides a method for treating or preventing cancer in a subject in need thereof, wherein an effective amount of a therapeutic composition as described herein is administered to the subject. The route of administration may, of course, vary depending on the location and nature of the disease to be treated, and may include, for example, intradermal, transdermal, subdermal, parenteral, intranasal, intravenous, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intratumoral, perfusion, lavage, direct injection, and oral administration. The encapsulated polynucleotide compositions described herein are particularly useful in the treatment of metastatic cancer, where systemic administration may be necessary to deliver the composition to multiple organs and / or cell types. Thus, in certain embodiments, the compositions described herein are administered systemically.

[0161] "Effective amount" or "effective dose", as used interchangeably herein, refers to an amount and / or dose of a composition described herein that results in an improvement or amelioration of symptoms of a disease or condition. An improvement is any improvement or amelioration of a disease or condition, or symptoms of a disease or condition. An improvement can be an observable or measurable improvement, or an improvement such that the subject generally feels better. Thus, those skilled in the art will recognize that a treatment may improve a disease condition, but may not be a complete cure of the disease. Improvements in a subject include, but are not limited to, reduced tumor burden, reduced tumor cell proliferation, increased tumor cell death, activation of immune pathways, increased time to tumor progression, reduced cancer pain, increased survival, or improved quality of life.

[0162] In some embodiments, administration of an effective dose can be achieved with administration of a single dose of the compositions described herein. As used herein, "dose" refers to the amount of composition delivered at one time. In some embodiments, the dose of the recombinant RNA molecule is 50% of the tissue culture infectious dose (TCID 50 In some embodiments, the TCID 50 is at least about 10 3 ~10 9 TCID50 / mL, e.g., at least about 10 3 TCID 50 / mL, about 10 4 TCID 50 / mL, about 10 5 TCID 50 / mL, about 10 6 TCID 50 / mL, about 10 7 TCID 50 / mL, about 10 8 TCID 50 / mL, or about 10 9 TCID 50 In some embodiments, the dose may be measured by the number of particles in a given volume (e.g., particles / mL). In some embodiments, the dose may be further refined by the number of genomic copies of the RNA polynucleotides described herein present in each particle (e.g., number of particles / mL, each particle containing at least one genomic copy of the polynucleotide). In some embodiments, delivery of an effective amount may require multiple administrations of the compositions described herein. Thus, administration of an effective dose may require administration of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or more doses of the compositions described herein.

[0163] In embodiments in which multiple doses of the compositions described herein are administered, each dose need not be administered by the same person and / or in the same geographic location. Furthermore, the doses can be administered according to a predetermined schedule. For example, the predetermined dosing schedule can include administering a dose of the compositions described herein daily, every other day, weekly, biweekly, monthly, bimonthly, annually, semi-annually, etc. The predetermined dosing schedule can be adjusted as needed for a given patient (e.g., the amount of the composition administered can be increased or decreased, and / or the frequency of the doses can be increased or decreased, and / or the total number of doses administered can be increased or decreased).

[0164] As used herein, "prevention" or "prophylaxis" can mean preventing a disease symptom altogether, delaying the onset of a disease symptom, or reducing the severity of a disease symptom that subsequently develops.

[0165] The term "subject" or "patient" as used herein is taken to mean any mammalian subject to which the compositions described herein are administered according to the methods described herein. In certain embodiments, the methods of the present disclosure are utilized to treat human subjects. The methods of the present disclosure can further be utilized to treat non-human primates (e.g., monkeys, baboons, and chimpanzees), mice, rats, cows, horses, cats, dogs, pigs, rabbits, goats, deer, sheep, ferrets, gerbils, guinea pigs, hamsters, bats, birds (e.g., chickens, turkeys, ducks), fish, and reptiles.

[0166] "Cancer" in this specification refers to or describes a physiological condition in mammals that is typically characterized by unregulated cell proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma, osteosarcoma, angiosarcoma, endothelial sarcoma, leiomyosarcoma, chordoma, lymphangiosarcoma, lymphangioendothelial sarcoma, rhabdomyosarcoma, fibrosarcoma, myxosarcoma, and chondrosarcoma), neuroendocrine tumor, mesothelioma, synovial sarcoma, schwannoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer, including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma, small cell lung cancer, peritoneal cancer, hepatocellular carcinoma, gastric or stomach cancer, including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, renal or kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, testicular cancer, esophageal cancer, biliary tract tumor, Ewing's tumor, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma. , sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndrome, heavy chain disease, neuroendocrine tumors, schwannoma, and other carcinomas, as well as head and neck cancer. In some embodiments, the cancer is a neuroendocrine cancer. Additionally, benign (i.e., non-cancerous) hyperproliferative diseases, disorders, conditions and conditions may also be treated using the teachings disclosed herein, including benign prostatic hyperplasia (BPH), meningiomas, schwannomas, neurofibromatosis, keloids, myomas, uterine fibroids, and the like.

[0167] Further Numbered Embodiments Further numbered embodiments of the present invention are provided as follows:

[0168] Embodiment 1. A lipid nanoparticle (LNP) comprising a synthetic RNA viral genome encoding an oncolytic virus.

[0169] Embodiment 2. The LNP of embodiment 1, wherein the oncolytic virus is a single-stranded RNA (ssRNA) virus.

[0170] Embodiment 3. The LNP of embodiment 1, wherein the oncolytic virus is a positive-sense ((+)-sense) ssRNA virus.

[0171] Embodiment 4. The LNP of embodiment 3, wherein the (+)-sense ssRNA virus is a picornavirus.

[0172] Embodiment 5. The LNP of embodiment 4, wherein the picornavirus is Seneca Valley virus (SVV) or Coxsackie virus.

[0173] Embodiment 6. The LNP of embodiment 5, wherein the SVV is an SVV-A selected from wild-type SVV-A (sequence number 1), an S177A-SVVA mutant (sequence number 2), an SVV-IR2 mutant (sequence number 3), and an SVV-IR2-S177A mutant (sequence number 4).

[0174] Embodiment 7 The LNP of embodiment 5, wherein the Coxsackie virus is selected from CVB3, CVA21, and CVA9.

[0175] Embodiment 8 The LNP of embodiment 5, wherein the Coxsackievirus is a modified CVA 21 virus comprising SEQ ID NO:27.

[0176] Embodiment 9. The LNP of any one of embodiments 1-8, wherein contacting the LNP with a cell results in production of viral particles by the cell, and the viral particles are infectious and lytic.

[0177] Embodiment 10 The LNP of any one of embodiments 1 to 9, wherein the synthetic RNA viral genome further comprises a heterologous polynucleotide encoding an exogenous payload protein.

[0178] Embodiment 11. The LNP of any one of embodiments 1 to 9, further comprising a recombinant RNA molecule encoding an exogenous payload protein.

[0179] Embodiment 12. The LNP of embodiment 10 or 11, wherein the exogenous payload protein is a fluorescent protein, an enzymatic protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand of a cell surface receptor.

[0180] Embodiment 13 The LNP of embodiment 12, wherein the cytokine is selected from IL-12, GM-CSF, IL-18, IL-2, and IL-36γ.

[0181] Embodiment 14 The LNP of embodiment 12, wherein the ligand for the cell surface receptor is Flt3 ligand or TNFSF14.

[0182] Embodiment 15 The LNP of embodiment 12, wherein the chemokine is selected from CCL21, CCL5, CXCL10, and CCL4.

[0183] Embodiment 16 The LNP of embodiment 12, wherein the antigen-binding molecule is capable of binding to and inhibiting an immune checkpoint receptor.

[0184] Embodiment 17. The LNP of embodiment 16, wherein the immune checkpoint receptor is PD-1.

[0185] Embodiment 18 The LNP of embodiment 12, wherein the antigen-binding molecule is capable of binding to a tumor antigen.

[0186] Embodiment 19. The LNP of embodiment 18, wherein the antigen-binding molecule is a bispecific T cell-associated molecule (BiTE) or a bispecific light T cell-associated molecule (LiTE).

[0187] Embodiment 20 The LNP of embodiment 18 or 19, wherein the tumor antigen is DLL3 or EpCAM.

[0188] Embodiment 21. The LNP of any one of embodiments 1 to 20, wherein the synthetic RNA viral genome and / or recombinant RNA molecule comprises a microRNA (miRNA) target sequence (miR-TS) cassette, and the miR-TS cassette comprises one or more miRNA target sequences.

[0189] Embodiment 22. The LNP of embodiment 21, wherein the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126.

[0190] Embodiment 23. The LNP of embodiment 22, wherein the miR-TS cassette comprises one or more copies of a miR-124 target sequence, one or more copies of a miR-1 target sequence, and one or more copies of a miR-143 target sequence.

[0191] Embodiment 24. The LNP of embodiment 22, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence.

[0192] Embodiment 25. The LNP of embodiment 22, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence.

[0193] Embodiment 26 The LNP of embodiment 22, wherein the miR-TS cassette comprises one or more copies of a miR-217 targeting sequence, one or more copies of a miR-137 targeting sequence, and one or more copies of a miR-126 targeting sequence.

[0194] Embodiment 27. The LNP of any one of embodiments 1 to 26, wherein the LNP comprises a cationic lipid, one or more helper lipids, and a phospholipid-polymer complex.

[0195] Embodiment 28. The LNP of embodiment 27, wherein the cationic lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly named SS-18 / 4PE-13), COATSOME® SS-EC (formerly named SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP).

[0196] Embodiment 29. The LNP of embodiment 27 or 28, wherein the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol.

[0197] Embodiment 30. The LNP of embodiment 27, wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0198] Embodiment 31. The LNP of any one of embodiments 27 to 30, wherein the phospholipid-polymer conjugate is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol (DPG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine).

[0199] Embodiment 32. The phospholipid-polymer complex is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PE 32. The LNP of any one of embodiments 27-31, wherein the LNP is selected from 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K).

[0200] Embodiment 33. The LNP of embodiment 27, wherein the cationic lipid comprises COATSOME® SS-OC, the one or more helper lipids comprise cholesterol (Chol) and DSPC, and the phospholipid-polymer complex comprises DPG-PEG2000.

[0201] Embodiment 34. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%.

[0202] Embodiment 35. The LNP of embodiment 33, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%.

[0203] Embodiment 36 The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5.

[0204] Embodiment 37. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%.

[0205] Embodiment 37A. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%.

[0206] Embodiment 37B. The LNP of embodiment 33, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%.

[0207] Embodiment 38. The LNP of embodiment 33, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%.

[0208] Embodiment 39. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 49:11:38.5:1.5.

[0209] Embodiment 39A. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=45%-65%, B=5%-20%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%.

[0210] Embodiment 39B. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=50%-60%, B=5%-15%, C=30%-45%, and D=0%-3%, and A+B+C+D=100%.

[0211] Embodiment 39C. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=55%-60%, B=5%-15%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%.

[0212] Embodiment 39D. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=55%-60%, B=5%-10%, C=30%-35%, and D=1%-2%, and A+B+C+D=100%.

[0213] Embodiment 39E. The LNP of embodiment 33, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 58:7:33.5:1.5.

[0214] Embodiment 40 The LNP of any one of embodiments 1 to 39E, wherein the LNP comprises a lipid formulation selected from Table 5.

[0215] Embodiment 41 The LNP of any one of embodiments 1 to 40, wherein the hyaluronan is complexed to the surface of the LNP.

[0216] Embodiment 42. A therapeutic composition comprising a plurality of lipid nanoparticles according to any one of embodiments 1 to 41.

[0217] Embodiment 43. The therapeutic composition of embodiment 42, wherein the plurality of LNPs have an average size of about 50 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm.

[0218] Embodiment 43A. The therapeutic composition of embodiment 42, wherein the plurality of LNPs have an average size of about 50 nm to about 120 nm.

[0219] Embodiment 43B. The therapeutic composition of embodiment 42, wherein the LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm.

[0220] Embodiment 43C. The therapeutic composition of embodiment 42, wherein the plurality of LNPs have an average size of about 100 nm.

[0221] Embodiment 44. The therapeutic composition of any one of embodiments 42-43C, wherein the plurality of LNPs have an average zeta potential between about 40 mV to about -40 mV, about 20 mV to about -20 mV, about 10 mV to about -10 mV, about 5 mV to about -5 mV, or about 20 mV to about -40 mV.

[0222] Embodiment 45. A therapeutic composition according to any one of embodiments 42-43C, wherein the plurality of LNPs have an average zeta potential of less than about -20 mV, less than about -30 mV, less than about -35 mV, or less than about -40 mV.

[0223] Embodiment 46. The therapeutic composition of embodiment 45, wherein the plurality of LNPs have an average zeta potential between about -50 mV to about -20 mV, about -40 mV to about -20 mV, or about -30 mV to about -20 mV.

[0224] Embodiment 47. The therapeutic composition of embodiment 45 or 46, wherein the plurality of LNPs have an average zeta potential of about -30mV, about -31mV, about -32mV, about -33mV, about -34mV, about -35mV, about -36mV, about -37mV, about -38mV, about -39mV, or about -40mV.

[0225] Embodiment 48. A therapeutic composition described in any one of embodiments 42 to 47, wherein, upon administration of the therapeutic composition to a subject, the recombinant RNA polynucleotide is delivered to a target cell of the subject, and the recombinant RNA polynucleotide produces an infectious oncolytic virus capable of lysing the target cell of the subject.

[0226] Embodiment 49. The therapeutic composition of embodiment 48, wherein the composition is formulated for intravenous or intratumoral delivery.

[0227] Embodiment 50. The therapeutic composition of embodiment 48, wherein the target cell is a cancerous cell.

[0228] Embodiment 51. A method for inhibiting the growth of a cancerous tumor in a subject in need thereof, comprising administering to a subject in need thereof a therapeutic composition described in any one of embodiments 42 to 50, wherein administration of the composition inhibits the growth of the tumor.

[0229] Embodiment 52. The method of embodiment 51, wherein the administration is intratumoral or intravenous.

[0230] Embodiment 53. The method of embodiment 51 or 52, wherein the cancer is lung cancer, liver cancer, melanoma, breast cancer, pancreatic cancer, prostate cancer, neuroblastoma, rhabdomyosarcoma, medulloblastoma, or bladder cancer.

[0231] Embodiment 53A. The method of any one of embodiments 51-53, wherein the cancer is a neuroendocrine cancer.

[0232] Embodiment 54. A recombinant RNA molecule comprising a synthetic RNA viral genome encoding an oncolytic virus.

[0233] Embodiment 55. The recombinant RNA molecule of embodiment 54, wherein the encoded oncolytic virus is a single-stranded RNA (ssRNA) virus.

[0234] Embodiment 56. The recombinant RNA molecule of embodiment 55, wherein the ssRNA virus is a positive-sense ((+)-sense) or negative-sense ((-)-sense) ssRNA virus.

[0235] Embodiment 57. The recombinant RNA molecule of embodiment 56, wherein the (+)-sense ssRNA virus is a picornavirus.

[0236] Embodiment 58. The recombinant RNA molecule of embodiment 57, wherein the picornavirus is Seneca Valley virus (SVV) or Coxsackie virus.

[0237] Embodiment 59. The recombinant RNA molecule of embodiment 58, wherein the SVV is an SVV-A selected from wild-type SVV-A (sequence number 1), an S177A-SVVA mutant (sequence number 2), an SVV-IR2 mutant (sequence number 3), or an SVV-IR2-S177A mutant (sequence number 4).

[0238] Embodiment 60. The recombinant RNA molecule of embodiment 58, wherein the Coxsackie virus is selected from CVB3, CVA21, and CVA9.

[0239] Embodiment 61 The recombinant RNA molecule of embodiment 58, wherein the Coxsackie virus is a modified CVA21 virus comprising SEQ ID NO:27.

[0240] Embodiment 62. A recombinant RNA molecule according to any one of embodiments 54 to 61, wherein the recombinant RNA molecule is capable of producing an infectious lytic virus when introduced into a cell by a non-viral delivery vehicle.

[0241] Embodiment 63. The recombinant RNA molecule of any one of embodiments 54 to 62, further comprising a microRNA (miRNA) target sequence (miR-TS) cassette inserted into the polynucleotide sequence encoding the oncolytic virus, wherein the miR-TS cassette comprises one or more miRNA target sequences, and expression of one or more of the corresponding miRNAs in the cell inhibits replication of the encoded virus in the cell.

[0242] Embodiment 64. The recombinant RNA molecule of embodiment 63, wherein the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126.

[0243] Embodiment 65. The recombinant RNA molecule of embodiment 64, wherein the miR-TS cassette comprises one or more copies of a miR-124 target sequence, one or more copies of a miR-1 target sequence, and one or more copies of a miR-143 target sequence.

[0244] Embodiment 66. The recombinant RNA molecule of embodiment 64, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence.

[0245] Embodiment 67. The recombinant RNA molecule of embodiment 64, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence.

[0246] Embodiment 68. The recombinant RNA molecule of embodiment 64, wherein the miR-TS cassette comprises one or more copies of a miR-217 target sequence, one or more copies of a miR-137 target sequence, and one or more copies of a miR-126 target sequence.

[0247] Embodiment 69. A recombinant RNA molecule according to any one of embodiments 54 to 68, wherein the recombinant RNA molecule is capable of producing a replication-competent oncolytic virus when introduced into a cell by a non-viral delivery vehicle.

[0248] Embodiment 70. The recombinant RNA molecule of embodiment 69, wherein the cell is a mammalian cell.

[0249] Embodiment 71. The recombinant RNA molecule of embodiment 70, wherein the cell is a mammalian cell present in a mammalian subject.

[0250] Embodiment 72. A recombinant RNA molecule according to any one of embodiments 54 to 71, wherein the replication-competent virus is selected from the group consisting of coxsackie virus, poliovirus, Seneca valley virus, lassa virus, murine leukemia virus, influenza A virus, influenza B virus, Newcastle disease virus, measles virus, sindbis virus, and maraba virus.

[0251] Embodiment 72A. A recombinant RNA molecule according to any one of embodiments 54 to 71, wherein the replication-competent virus is selected from those listed in Table 1.

[0252] Embodiment 73. The recombinant RNA molecule of embodiment 63, wherein one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more essential viral genes.

[0253] Embodiment 74. The recombinant RNA molecule of embodiment 63, wherein one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more non-essential genes.

[0254] Embodiment 74A. The recombinant RNA molecule of embodiment 63, wherein one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more essential viral genes.

[0255] Embodiment 75. A recombinant RNA molecule according to any one of embodiments 54 to 74A, wherein the recombinant RNA molecule is inserted into a nucleic acid vector.

[0256] Embodiment 76 The recombinant RNA molecule of embodiment 75, wherein the nucleic acid vector is a replicon.

[0257] Embodiment 77. A recombinant RNA molecule according to embodiments 54 to 76, wherein the synthetic RNA viral genome further comprises a heterologous polynucleotide encoding an exogenous payload protein.

[0258] Embodiment 78. The recombinant RNA molecule of embodiment 77, wherein the exogenous payload protein is a fluorescent protein, an enzyme protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand capable of binding to a cell surface receptor.

[0259] Embodiment 79. The recombinant RNA molecule of embodiment 78, wherein the cytokine is selected from IL-12, GM-CSF, IL-18, IL-2, and IL-36γ.

[0260] Embodiment 80. The recombinant RNA molecule of embodiment 78, wherein the ligand of the cell surface receptor is Flt3 ligand or TNFSF14.

[0261] Embodiment 81. The recombinant RNA molecule of embodiment 78, wherein the chemokine is selected from CCL21, CCL5, CXCL10, and CCL4.

[0262] Embodiment 82. The recombinant RNA molecule of embodiment 78, wherein the antigen binding molecule is capable of binding to and inhibiting an immune checkpoint receptor.

[0263] Embodiment 83. The recombinant RNA molecule of embodiment 82, wherein the immune checkpoint receptor is PD-1.

[0264] Embodiment 84 The recombinant RNA molecule of embodiment 78, wherein the antigen-binding molecule is capable of binding to a tumor antigen.

[0265] Embodiment 85. The recombinant RNA molecule of embodiment 84, wherein the antigen-binding molecule is a bispecific T cell-associated molecule (BiTE) or a bispecific light T cell-associated molecule (LiTE).

[0266] Embodiment 86. The recombinant RNA molecule of embodiment 84 or 85, wherein the tumor antigen is DLL3 or EpCAM.

[0267] Embodiment 87. A recombinant DNA molecule comprising, from 5' to 3', a promoter sequence, a 5' junction cleavage sequence, a polynucleotide sequence encoding a recombinant RNA molecule described in any one of embodiments 54 to 86, and a 3' junction cleavage sequence.

[0268] Embodiment 88. The recombinant DNA molecule of embodiment 87, wherein the promoter sequence is a T7 promoter sequence.

[0269] Embodiment 89. The recombinant DNA molecule of embodiment 87 or 88, wherein the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a ribozyme sequence.

[0270] Embodiment 90. The recombinant DNA molecule of embodiment 89, wherein the 5' ribozyme sequence is a hammerhead ribozyme sequence and the 3' ribozyme sequence is a hepatitis delta virus ribozyme sequence.

[0271] Embodiment 91. The recombinant DNA molecule of embodiment 87 or 88, wherein the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a restriction enzyme recognition sequence.

[0272] Embodiment 92. The recombinant DNA molecule of embodiment 91, wherein the 5' ribozyme sequence is a hammerhead ribozyme sequence, a pistol ribozyme sequence, or a modified pistol ribozyme sequence.

[0273] Embodiment 93. The recombinant DNA molecule of embodiment 91 or 92, wherein the 3' restriction enzyme recognition sequence is a type IIS restriction enzyme recognition sequence.

[0274] Embodiment 94. A recombinant DNA molecule according to embodiment 93, wherein the type IIS recognition sequence is a SapI recognition sequence.

[0275] Embodiment 95. The recombinant DNA molecule of embodiment 87 or 88, wherein the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a restriction enzyme recognition sequence.

[0276] Embodiment 96. A method for producing a recombinant RNA molecule according to any one of embodiments 54 to 86, comprising in vitro transcription of a DNA molecule according to any one of embodiments 87 to 95 and purification of the resulting recombinant RNA molecule.

[0277] Embodiment 98. The method of embodiment 96, wherein the recombinant RNA molecule comprises 5' and 3' ends that are native to the oncolytic virus encoded by the synthetic RNA virus genome.

[0278] Embodiment 99. A composition comprising an effective amount of a recombinant RNA molecule according to any one of embodiments 54 to 86 and a carrier suitable for administration to a mammalian subject.

[0279] Embodiment 100. A particle comprising a recombinant RNA molecule according to any one of embodiments 54 to 86.

[0280] Embodiment 101. The particle of embodiment 100, wherein the particle is biodegradable.

[0281] Embodiment 102. The particle described in embodiment 101, wherein the particle is selected from the group consisting of nanoparticles, exosomes, liposomes, and lipoplexes.

[0282] Embodiment 103. The particle described in embodiment 102, wherein the exosomes are modified exosomes derived from intact exosomes or empty exosomes.

[0283] Embodiment 104. The particle described in embodiment 102, wherein the nanoparticle is a lipid nanoparticle (LNP) comprising a cationic lipid, one or more helper lipids, and a phospholipid-polymer complex.

[0284] Embodiment 105. Particles according to embodiment 104, wherein the cationic lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly SS-18 / 4PE-13), COATSOME® SS-EC (formerly SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP).

[0285] Embodiment 106. A particle according to embodiment 104 or 105, wherein the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol.

[0286] Embodiment 107. The LNP of embodiment 104, wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0287] Embodiment 108. The phospholipid-polymer complex is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol (DPG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG ... 107. The particle according to any one of embodiments 104 to 106, wherein the particle is selected from the group consisting of 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine).

[0288] Embodiment 109. The phospholipid-polymer complex is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PE 109. The particle according to any one of embodiments 104 to 108, wherein the glyceryl ester is selected from the group consisting of 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K).

[0289] Embodiment 110. A particle described in embodiment 104, wherein the cationic lipid comprises COATSOME (registered trademark) SS-OC, the one or more helper lipids comprise cholesterol (Chol) and DSPC, and the phospholipid-polymer complex comprises DPG-PEG2000.

[0290] Embodiment 111. Particles described in embodiment 110, in which the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%.

[0291] Embodiment 112. Particles described in embodiment 110, in which the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%.

[0292] Embodiment 113. A particle according to embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5.

[0293] Embodiment 114. Particles described in embodiment 110, in which the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%.

[0294] Embodiment 114A. Particles described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%.

[0295] Embodiment 114B. Particles described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%.

[0296] Embodiment 115. Particles described in embodiment 110, in which the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%.

[0297] Embodiment 116. A particle according to embodiment 110, in which the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 49:11:38.5:1.5.

[0298] Embodiment 116A. Particles described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=45%-65%, B=5%-20%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%.

[0299] Embodiment 116B. Particles described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=50%-60%, B=5%-15%, C=30%-45%, and D=0%-3%, and A+B+C+D=100%.

[0300] Embodiment 116C. Particles described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=55%-60%, B=5%-15%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%.

[0301] Embodiment 116D. Particles described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is approximately A:B:C:D, where A=55%-60%, B=5%-10%, C=30%-35%, and D=1%-2%, and A+B+C+D=100%.

[0302] Embodiment 116E. A particle described in embodiment 110, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 58:7:33.5:1.5.

[0303] Embodiment 117. A particle according to any one of embodiments 100 to 116E, wherein the LNP comprises a lipid formulation selected from Table 5.

[0304] Embodiment 118. A particle according to embodiment 104, wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

[0305] Embodiment 119. A particle according to embodiment 104 or 118, further comprising a phospholipid-polymer complex, wherein the phospholipid-polymer complex is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine).

[0306] Embodiment 120. A particle according to any one of embodiments 104 to 119, wherein hyaluronan is complexed to the surface of the LNP.

[0307] Embodiment 121. A particle according to any one of embodiments 104 to 119, further comprising a second recombinant RNA molecule encoding a payload molecule.

[0308] Embodiment 122. The particle of embodiment 121, wherein the second recombinant RNA molecule is a replicon.

[0309] Embodiment 123. The particle of embodiment 122, wherein the second recombinant RNA molecule is an alphavirus replicon.

[0310] Embodiment 124. A therapeutic composition comprising a plurality of lipid nanoparticles according to any one of embodiments 104 to 123.

[0311] Embodiment 125. The therapeutic composition of embodiment 124, wherein the plurality of LNPs have an average size of about 50 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm.

[0312] Embodiment 125A. The therapeutic composition of embodiment 124, wherein the plurality of LNPs have an average size of about 50 nm to about 120 nm.

[0313] Embodiment 125B. The therapeutic composition of embodiment 124, wherein the plurality of LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm.

[0314] Embodiment 125C. The therapeutic composition of embodiment 124, wherein the plurality of LNPs have an average size of about 100 nm.

[0315] Embodiment 126. A therapeutic composition according to any one of embodiments 124 to 125C, wherein the plurality of LNPs have an average zeta potential between about 40 mV to about -40 mV, about 20 mV to about -20 mV, about 10 mV to about -10 mV, about 5 mV to about -5 mV, or about 20 mV to about -40 mV.

[0316] Embodiment 127. A therapeutic composition according to any one of embodiments 124 to 125C, wherein the plurality of LNPs have an average zeta potential of less than about -20 mV, less than about -30 mV, less than about -35 mV, or less than about -40 mV.

[0317] Embodiment 128. A therapeutic composition according to any one of embodiments 124 to 125C, wherein the plurality of LNPs have an average zeta potential between about -50 mV and about -20 mV, about -40 mV and about -20 mV, or about -30 mV and about -20 mV.

[0318] Embodiment 129. A therapeutic composition according to any one of embodiments 124 to 125C, wherein the plurality of LNPs have an average zeta potential of about -30mV, about -31mV, about -32mV, about -33mV, about -34mV, about -35mV, about -36mV, about -37mV, about -38mV, about -39mV, or about -40mV.

[0319] Embodiment 130. A therapeutic composition described in any one of embodiments 124 to 129, wherein delivery of the composition to a subject delivers the encapsulated recombinant RNA-expressing molecule to a target cell, and the encapsulated recombinant RNA molecule produces an infectious virus capable of lysing the target cell.

[0320] Embodiment 131. The therapeutic composition of embodiment 130, wherein the composition is formulated for intravenous or intratumoral delivery.

[0321] Embodiment 132. The therapeutic composition of embodiment 131, wherein the target cells are cancerous cells.

[0322] Embodiment 133. An inorganic particle comprising a recombinant polynucleotide according to any one of embodiments 54 to 86.

[0323] Embodiment 134. The inorganic particles according to embodiment 133, wherein the inorganic particles are selected from the group consisting of gold nanoparticles (GNPs), gold nanorods (GNRs), magnetic nanoparticles (MNPs), magnetic nanotubes (MNTs), carbon nanohorns (CNHs), carbon fullerenes, carbon nanotubes (CNTs), calcium phosphate nanoparticles (CPNPs), mesoporous silica nanoparticles (MSNs), silica nanotubes (SNTs), or star-shaped hollow silica nanoparticles (SHNPs).

[0324] Embodiment 135. The inorganic particle of embodiment 133, further comprising a second recombinant RNA molecule encoding a payload molecule.

[0325] Embodiment 136 The particle of embodiment 135, wherein the second recombinant RNA molecule is a replicon.

[0326] Embodiment 137. A composition comprising inorganic particles according to any one of embodiments 133 to 136, wherein the average diameter of the particles is less than about 500 nm, is between about 50 nm and 500 nm, is between about 250 nm and about 500 nm, or is about 350 nm.

[0327] Embodiment 138. A method for killing a cancerous cell, comprising exposing the cancerous cell to a particle described in any one of embodiments 1 to 41, 100 to 123, or 133 to 136, a recombinant RNA molecule described in any one of embodiments 54 to 86, or a composition thereof, under conditions sufficient to intracellularly deliver the particle to the cancerous cell, wherein a replication-competent virus produced by the encapsulated polynucleotide results in killing of the cancerous cell.

[0328] Embodiment 139. The method of embodiment 138, wherein replication-competent virus is not produced in non-cancerous cells.

[0329] Embodiment 140. The method according to embodiment 138 or 139, wherein the method is carried out in vivo, in vitro, or ex vivo.

[0330] Embodiment 141. A method for treating cancer in a subject, comprising administering to a subject suffering from cancer an effective amount of a particle described in any one of embodiments 1 to 41, 100 to 123, or 133 to 136, a recombinant RNA particle described in any one of embodiments 54 to 86, or a composition thereof.

[0331] Embodiment 142. The method of embodiment 141, wherein the particles or compositions thereof are administered intravenously, intranasally, as an inhalant, or injected directly into the tumor.

[0332] Embodiment 143. The method of embodiment 141 or 142, wherein the particles or compositions thereof are repeatedly administered to the subject.

[0333] Embodiment 144. The method of any of embodiments 141 to 143, wherein the subject is a mouse, a rat, a rabbit, a cat, a dog, a horse, a non-human primate, or a human.

[0334] Embodiment 145. The method of any of embodiments 141 to 144, wherein the cancer is selected from lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), sarcoma, neuroblastoma, rhabdomyosarcoma, medulloblastoma, bladder cancer, and marginal zone lymphoma (MZL).

[0335] Embodiment 146. The method of embodiment 145, wherein the lung cancer is small cell lung cancer or non-small cell lung cancer.

[0336] Embodiment 147. The method of embodiment 145, wherein the liver cancer is hepatocellular carcinoma (HCC).

[0337] Embodiment 148. The method of embodiment 145, wherein the prostate cancer is neuroendocrine prostate cancer that emerges during treatment.

[0338] Embodiment 148A. The method of any one of embodiments 141-148, wherein the cancer is a neuroendocrine cancer. EXAMPLES

[0339] The following examples are provided for the purpose of illustrating various embodiments of the present disclosure and are not meant to limit the disclosure in any manner. The examples presented, together with the methods described herein, are representative of preferred embodiments presented, are exemplary, and are not intended to limit the scope of the disclosure. Modifications therein and other uses encompassed by the spirit of the disclosure as defined by the scope of the claims will occur to those skilled in the art.

[0340] Example 1. Production of infectious picornavirus viruses from recombinant RNA molecules Experiments were performed to evaluate the ability to produce infectious SVV virus from recombinant RNA molecules. Briefly, RNA polynucleotides containing the SVV viral genome were generated in vitro by T7 transcription, 293T cells were transfected with 1 μg of SVV RNA constructs with Lipofectamine RNAiMax for 4 h, cells were washed, and complete medium was added to each well. Supernatants from transfected 293T were collected after 72 h, syringe filtered through a 0.45 μM filter, and serially diluted against NCI-H1299 cells. After 48 h, supernatants were removed from NCI-H1299 cultures, and cells were stained with crystal violet to assess viral infectivity. As shown in Figure 1B, RNA molecules containing the SVV-WT genome produced active lytic virus.

[0341] In addition, supernatants of NCI-H1299 cells treated with 1 μg of SVV-WT RNA lipid, SVV-WT plasmid DNA, or SVV negative pDNA control were collected after 72 hours and serially diluted against uninfected NCI-H1299 cells. Cell viability assays were performed according to standard protocols. As shown in Figure 2, SVV-WT RNA / LNPs can produce infectious virus that leads to tumor cell lysis in vitro.

[0342] Example 2. Formulation of lipid nanoparticles for intravenous delivery of RNA encoding SVV Recombinant RNA molecules containing the SVV genome were formulated into lipid nanoparticles for delivery of the RNA in vivo.

[0343] Production of lipid nanoparticles: The following lipids were used in the formulation of lipid nanoparticles: (a) D-Lin-MC3-DMA(MC3); (b) N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP) (c) COATSOME (registered trademark) SS-LC (formerly known as SS-18 / 4PE-13), (d) COATSOME (registered trademark) SS-EC (formerly known as SS-33 / 4PE-15), (e) COATSOME® SS-OC, (f) COATSOME® SS-OP, (g) Di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319) (h) cholesterol, (i) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), (j) 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), (k) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), (l) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), (m) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), (n) 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), (o) 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), and (p) 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K).

[0344] Lipids were prepared in ethanol at various ratios as shown in Table 5 below. RNA-lipid nanoparticles were then produced using a microfluidic micromixer (Precision NanoSystems, Vancouver, BC) at a total flow rate of 2 mL / min (ethanol, 0.5 mL / min for lipid mixture, aqueous buffer, 1.5 mL / min for DNA). The resulting particles were washed by tangential flow filtration with PBS containing Ca and Mg. Exemplary SVV LNP formulations are provided in Table 5. Unless otherwise indicated, each of the encapsulated RNA genomes was produced from an IVT template containing a 5' hammerhead ribozyme and a 3' hepatitis delta ribozyme. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7] [Table 5-8] [Table 5-9]

[0345] Analysis of lipid nanoparticle physical properties: The lipid nanoparticle physical properties in Table 5 were evaluated before and after tangential flow filtration. Particle size distribution and zeta potential measurements were determined by light scattering using a Malvern Nano-ZS Zetasizer (Malvern Instruments Ltd, Worcestershire, UK). Size measurements were performed in HBS at pH 7.4 and zeta potential measurements were performed in 0.01 M HBS at pH 7.4. Percentage of RNA capture was measured by Ribogreen assay. Lipid nanoparticles that showed more than 80 percent RNA capture were tested in vivo.

[0346] The physical characteristics of the various lipid nanoparticle formulations are shown in Table 6 below. [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5]

[0347] Varying the lipid composition and lipid ratio alters nanoparticle size and / or RNA capture, as shown in Figures 3A-3D and Table 6. Lipid nanoparticles that demonstrated greater than 80% RNA capture were tested in vivo in Examples 4-18 described below.

[0348] Example 3: Lipid nanoparticles containing RNA encoding SVV produce infectious virus and inhibit tumor growth in vivo Experiments were performed to determine the ability of lipid nanoparticles containing SVV-WT RNA to produce infectious virus in vivo to inhibit tumor growth in mice.

[0349] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles were performed as described in Example 3 and are summarized in Table 7 below. [Table 7]

[0350] The ability of SVV RNA lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model. 6 NCI-H1299 cells were suspended in 0.1 mL of serum-free DPBS and Matrigel (1:1 vol / vol) and inoculated subcutaneously into the right flank of 8-week-old female athymic nude mice (Charles River Laboratories). Mice were randomly assigned to experimental groups and were cultured until the median tumor size reached approximately 150 mm. 3 (120~180mm 3 Treatment was initiated when the range of

[0351] Two doses of lipid nanoparticles (5 μg / dose) containing SVV-WT RNA were administered intravenously on days 1 and 8. Tumor volumes were measured three times a week using electronic calipers. On day 16, tumors were harvested for evaluation of infectious virus.

[0352] As shown in Figure 4A, mice treated with SVV-WT lipid nanoparticles showed a significant reduction in tumor growth compared to mice treated with PBS (2-way RM ANOVA, p<0.001). Furthermore, as shown in Figure 4B, treatment with SVV-WT lipid nanoparticles did not affect body weight, suggesting that lipid nanoparticles are non-toxic when administered intravenously. Figures 5A and 5B show the recovery of infectious SVV from tumors following intravenous administration of SVV-WT lipid nanoparticles.

[0353] Example 4: Particles containing RNA molecules encoding gain-of-function SVV inhibited tumor growth Experiments were performed to determine the ability of lipid nanoparticles containing RNA molecules encoding SVV with a gain-of-function mutation (SVV-S177A) to produce infectious virus in vivo to inhibit tumor growth in mice.

[0354] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles were performed as described in Example 3 and are summarized in Table 8 below. [Table 8]

[0355] The ability of SVV RNA lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 3. Briefly, 5×10 6 NCI-H1299 cells were inoculated subcutaneously into the right flank of 8-week-old female hypothymic nude mice. Mice were randomly assigned to four experimental groups: (i) PBS only, (ii) SVV-negative (SVV-Neg, formulation no. 70009-1.C), (iii) SVV (wild type, formulation no. 70009-2.C), and (iv) SVV-S177A (formulation no. 70009-3.C). SVV-Neg lipid nanoparticles were composed of RNA molecules that cannot replicate but are similar in size to SVV-WT and SVV-S177A RNA. Median tumor size was approximately 150 mm. 3 When tumor volume reached 100%, lipid nanoparticles (5 μg / dose) were administered intravenously on day 1, followed by additional treatments on days 6, 11, and 16. Tumor volumes were measured three times a week using electronic calipers. On day 22, mice were sacrificed, tumor and liver tissues were harvested, and the presence of replicated infectious virus was determined by measuring the presence of negative-strand SVV RNA (a surrogate marker for replicating SVV) using qRT-PCR.

[0356] As shown in Figure 6A, mice treated with SVV-WT or SVV-S177A lipid nanoparticles significantly inhibited tumor growth compared to mice treated with SVV-Neg lipid nanoparticles or PBS (p<0.05, 2-way ANOVA). Administration of SVV lipid nanoparticles had minimal effect on body weight throughout the course of the study (Figure 6B), suggesting that lipid nanoparticles containing RNA molecules encoding SVV are non-toxic and well tolerated.

[0357] Active replication of SVV was detected in tumor tissue of mice treated with lipid nanoparticles containing SVV-WT or SVV-S177A RNA molecules (Figure 6C). Importantly, active viral replication did not occur in liver tissue of any treatment group, including mice that received lipid nanoparticles capable of producing infectious virus in tumor tissue (Figure 6D).

[0358] Example 5: Lipid nanoparticles containing RNA molecules encoding SVV inhibit tumor growth Experiments were performed to determine the ability of lipid nanoparticles containing RNA molecules encoding SVV to produce infectious virus in vivo and inhibit tumor growth.

[0359] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles are described in Example 2 and Table 9 below. [Table 9]

[0360] The ability of SVV RNA lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 H1299 cells were inoculated subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3Upon reaching 18 days, mice were administered two 5 μg doses of SVV lipid nanoparticles containing MC-3, SS-LC, or SS-EC ionizable lipids (formulations shown in Table 9 above) intravenously on days 1 and 6. Tumor volumes were measured three times a week using electronic calipers. On day 12, tumor tissue was harvested and analyzed for the presence of negative-strand SVV RNA (a surrogate marker for replicating SVV) using qRT-PCR.

[0361] As shown in Figure 7, mice treated with MC3-based lipid nanoparticles (formulation no. 70053-1.C) showed significant inhibition of tumor growth compared to mice treated with PBS (F-test for comparison of variances **p<0.01). However, SS-LC-based or SS-EC-based lipid nanoparticles (formulation nos. 70053-2.C, 70059-1.C, or 70059-2.C) had no inhibitory effect on tumor growth. These data suggest that MC3-based lipid nanoparticles deliver RNA molecules encoding SVV to tumor tissue, leading to the production of infectious virus and tumor lysis in vivo.

[0362] Example 6: In vivo efficacy of lipid nanoparticles containing RNA encoding SVV in small cell lung cancer Experiments were performed to determine the ability of lipid nanoparticles containing RNA molecules encoding SVV to produce infectious virus in vivo and inhibit the growth of small cell lung cancer (SCLC).

[0363] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles are described in Example 2 and Table 10 below. [Table 10]

[0364] The in vivo efficacy of SVV-encoding RNA lipid nanoparticles on SCLC was tested using an H82 xenograft model. Briefly, NCI-H82 cells (1×10 in a 1:1 mixture of serum-free PBS and Matrigel®) were cultured in a 1×10 2 x 10 6-well plate. 6100 cells / 0.1 mL) were inoculated subcutaneously into the right flank of 8-week-old female athymic nude mice (Charles River Laboratories). Mice developed median tumor sizes of approximately 150 mm 3 (120~180mm 3 Treatment was initiated when tumor volume reached 10 μg / mL (range 0.01 μg / mL) and administered intravenously with 10 μg SV-WT lipid nanoparticles (formulation no. 70087-1C) on days 1, 6, 11, and 16, or intratumorally with 1 μg SVV-WT RNA formulated in Lipofectamine RNAiMax (positive control) on days 1 and 4. Tumor volumes were measured three times a week using electronic calipers.

[0365] As shown in Figure 8, mice treated with SVV-WT lipid nanoparticles or SVV-WT RNA formulated with Lipofectamine showed significant inhibition of tumor growth compared to mice treated with PBS (2-way ANOVA p<0.05). These results indicate that either intravenous administration of lipid nanoparticles containing RNA molecules encoding SVV or intratumoral administration of RNA molecules encoding SVV formulated with Lipofectamine effectively initiates viral replication in tumor tissue, resulting in tumor cell lysis.

[0366] Example 7: Mutation of lipid composition can alter the antitumor activity of SVV-encoding RNA nanoparticles Experiments were performed to determine whether the lipid composition of nanoparticles containing RNA molecules encoding SVV affected viral replication and antitumor activity in vivo.

[0367] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles are described in Example 2 and Table 11 below. Table 11. SVV RNA lipid nanoparticle formulations [Table 11]

[0368] The ability of SVV RNA lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were inoculated subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3 Upon reaching 18 days, mice were administered 5 μg of lipid nanoparticles (formulations shown in Table 11 above) intravenously on days 1 and 6. Tumor volumes were measured three times a week using electronic calipers. On day 12, tumor tissues were harvested and analyzed for the presence of negative strand SVV RNA (a surrogate marker for replicating SVV) using qRT-PCR.

[0369] As shown in FIG. 9A, mice treated with both MC3-based and OC-based lipid nanoparticles (formulations no. 70077-3.C, 70077-4.C, 70077-8.C, 70077-10.C, and 70077-11.C) had significantly inhibited tumor growth compared to mice treated with PBS (2-way ANOVA, Tukey's multiple comparison test, ****: p<0.0001 vs. PBS). Tumor tissues from mice treated with different lipid nanoparticle formulations showed the presence of negative-strand SVV RNA, confirming that intravenous administration of SVV-WT RNA lipid nanoparticles induced viral replication in tumor tissue (FIG. 9D). MC3-based lipid nanoparticles caused weight loss and increases in liver enzymes AST and ALT, whereas OC-based lipid nanoparticles had no effect on these parameters (FIGS. 9B and 9C). Collectively, these data indicated that OC-based lipid nanoparticle formulations significantly inhibited tumor growth and were well tolerated in mice.

[0370] Example 8: PEG composition alters lipid nanoparticle antitumor activity Experiments were performed to determine whether the PEG composition of lipid nanoparticles containing RNA molecules encoding SVV affects viral replication and antitumor activity in vivo.

[0371] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles are described in Example 2 and Table 12 below. [Table 12]

[0372] The ability of SVV RNA lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were inoculated subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3 When tumor volume reached 100 mg / kg / day, two doses of lipid nanoparticles (5 μg / dose) containing RNA molecules encoding SVV were administered intravenously on days 1, 6, 11, and 16. Tumor volumes were measured three times a week using electronic calipers.

[0373] As shown in Figure 10, mice treated with formulations 70087-1.C and 70087-4.C (Table 12) showed significant inhibition of tumor growth compared to mice treated with PBS (2-way ANOVA, Tukey's multiple comparison test, ****: p<0.0001 and ***: p<0.001 vs. PBS). Only formulations 70087-2.C and 70087-3.C differ from 70087-4.C in the type of PEGylated lipid used in the formulation (Table 12). These findings suggest that the type of PEGylated lipid may have a significant effect on the antitumor activity of SVV-encoding RNA nanoparticles.

[0374] Example 9: PEG composition alters OC-based lipid nanoparticle antitumor activity Experiments were performed to determine whether the PEG composition of lipid nanoparticles containing RNA molecules encoding SVV affects viral replication and antitumor activity in vivo.

[0375] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles are described in Example 2 and Table 13 below. [Table 13]

[0376] The ability of SVV RNA lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were injected subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3 Upon reaching 18 h post-treatment, mice were intravenously administered 5 μg of SVV RNA lipid nanoparticles containing either DSPE-PEG5K, or DPG-, DMG-, or DSG-PEG2K (formulations shown in Table 13). Tumor tissues were collected from mice 72 hours after treatment and analyzed for the presence of negative-strand SVV RNA (a surrogate marker for replicating SVV) using qRT-PCR.

[0377] As shown in Figure 11, the PEG type used in the formulation can modify the ability of the nanoparticles to efficiently deliver the SVV genome to tumor tissue. Tumors from mice treated with formulations 80010-2.C, 80010-3.C, and 80010-4.C showed more SVV minus strand or SVV replication. Only formulations 80010-2.C, 80010-3.C, 80010-4.C, and 80010-5.C differ from each other in the type and percentage of lipid-PEG used in the formulation. This indicated that the choice of PEG type and the percentage used can have a significant effect on the biological activity of these nanoparticles.

[0378] Example 10: Ionizable lipid composition alters lipid nanoparticle antitumor activity Experiments were performed to determine whether the ionizable lipid composition affects the antitumor activity of lipid nanoparticles containing RNA molecules encoding SVV in vivo.

[0379] A description of lipid nanoparticle production, formulation, and analysis of the physical properties of SVV RNA lipid nanoparticles is provided in Example 2 and Table 14 below. [Table 14]

[0380] The ability of the ionizable lipid composition of the SVV RNA-lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were injected subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3 When tumor volume reached 100 mg / kg, mice were intravenously administered SVV-S177A RNA-lipid nanoparticles containing 1 mg / kg ionizable lipid of SS-OC (formulation no. 80033-1.C), SS-LC (formulation no. 80033-2.C), or SS-OP (formulation no. 80033-3.C) on study days 1 and 8. Tumor volumes were measured three times a week using electronic calipers.

[0381] As shown in Figure 12, mice treated with SS-OC- or SS-OP-based lipid nanoparticles showed significant inhibition of tumor growth compared to mice treated with PBS or SS-LC-based lipid nanoparticles (2-way ANOVA, Tukey's multiple comparison test, *p<0.05, **p<0.001 vs. PBS). These results indicate that the ionizable lipid composition affects the antitumor activity of SVV RNA lipid nanoparticles in vivo.

[0382] Example 11: In vivo efficacy of lipid nanoparticles containing RNA encoding SVV in small cell lung cancer Experiments were performed to determine the ability of lipid nanoparticles containing RNA molecules encoding SVV to produce infectious virus in vivo and inhibit the growth of small cell lung cancer (SCLC).

[0383] The production, formulation, and physical property analysis of SVV RNA-lipid nanoparticles are described in Example 2 and Table 15 below. [Table 15]

[0384] The in vivo efficacy of SVV-encoding RNA lipid nanoparticles on SCLC was tested using the H446 xenograft model. Briefly, NCI-H82 cells (5×10 in a 1:1 mixture of serum-free PBS and Matrigel®) were cultured in a 1:1 mixture of PBS and Matrigel®. 6 100 cells / 0.1 mL) were inoculated subcutaneously into the right flank of 8-week-old female athymic nude mice (Charles River Laboratories). The median tumor size was approximately 150 mm. 3 (120~180mm 3 When tumor volume reached 100 μg / kg (range 0.01 mg / kg / day), mice were intravenously administered 1 mg / kg of SVV-Neg (formulation no. 80059-1.C) or SVV-S177A (formulation no. 80059-2.C) RNA-lipid nanoparticles or PBS on days 1, 8, and 15. Tumor volumes were measured three times a week using electronic calipers. On day 22, tumors were harvested and analyzed for the presence of negative-strand SVV RNA (a surrogate marker for replicating SVV) using qRT-PCR.

[0385] As shown in Figure 13A, mice treated with SVV-S177A lipid nanoparticles showed significant inhibition of tumor growth compared to mice treated with SVV-Neg lipid nanoparticles or PBS (2-way ANOVA, p<0.0.001). Importantly, intravenous administration of SVV-encoding RNA lipid nanoparticles did not affect body weight, suggesting that these agents were non-toxic and well tolerated (Figure 13B). Tumor tissue from mice treated with SVV-S177A RNA lipid nanoparticle formulations showed the presence of negative-strand SVV RNA, indicating that intravenous administration of SVV-WT RNA lipid nanoparticles induced viral replication in tumor tissue (Figure 13C). These results indicate that systemic administration of SVV-S177A RNA lipid nanoparticles results in SVV replication and lysis of SCLC cells in vivo.

[0386] Example 12: In vivo efficacy of SVV-IRES2 RNA lipid nanoparticles against tumor growth Experiments were performed to determine whether lipid nanoparticles containing SVV-IRES2 RNA could inhibit tumor growth in vivo.

[0387] The production, formulation, and analysis of SVV RNA-lipid nanoparticles is described in Example 2 and Table 16 below. [Table 16]

[0388] The ability of SVV-WT and SVV-IRES2 lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were injected subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3When tumor volume reached 100 mg / kg, mice were intravenously administered lipid nanoparticles containing 0.2 mg / kg of SVV-WT (formulation no. 80130-1.C) or SVV-IRES2 (formulation no. 80130-2.C) RNA molecules (day 1). Subsequent doses of PBS or lipid nanoparticles were administered on day 8 of the study. Tumor volumes were measured 3 times a week using electronic calipers.

[0389] As shown in Figure 14, mice treated with SVV-WT RNA or SVV-IRES2 RNA lipid nanoparticles showed significantly lower tumor burden compared to mice treated with PBS (2-way ANOVA, Tukey's multiple comparison test, ****p<0.0001). These results indicate that lipid nanoparticles containing SVV-WT or SVV-IRES2 RNA molecules exhibit antitumor activity in vivo, with SVV-IRES2 showing the best antitumor effect.

[0390] Example 13: Lipid nanoparticles containing RNA molecules encoding SVV IRES2 are able to replicate in neuroblastoma tumors Experiments were performed to determine the ability of SVV-WT and SVV-IRES2 RNA lipid nanoparticles to replicate in vivo.

[0391] The production, formulation, and analysis of SVV RNA-lipid nanoparticles is described in Example 2 and Table 17 below. [Table 17]

[0392] The ability of SVV-WT and SVV-IRES2 lipid nanoparticles to inhibit tumor growth was evaluated using the N1E-115 xenograft model. Briefly, N1E-115 cells (5 × 10 in a 1:1 mixture of serum-free PBS and Matrigel) were cultured in vitro. 5 100 cells / 0.1 mL) were inoculated subcutaneously into the right flank of 8-week-old female A / J mice (Charles River Laboratories). Median tumor size was approximately 150 mm. 3 (120~180mm 3When tumors reached tumor size (range 0-100 mg / kg), mice were intravenously administered 0.4 mg / kg SVV-WT (formulation no. 80130-1.C) or SVV-IRES2 (formulation no. 80130-2.C) RNA lipid nanoparticles (day 1). Tumors were harvested from mice 96 hours after lipid nanoparticle treatment and analyzed for the presence of negative-strand SVV RNA (a surrogate marker for replicating SVV) using qRT-PCR.

[0393] As shown in Figure 15, mice administered SVV-WT or SVV-IRES2 RNA lipid nanoparticles exhibited 10- to 1000-fold higher levels of negative-strand SVV RNA compared to PBS controls. Notably, the majority of tumor tissues from mice treated with SVV-IRES2 lipid nanoparticles exhibited higher levels of SVV replication compared to mice administered SVV-WT RNA lipid nanoparticles. These results indicate that systemic administration of SVV-WT or SVV-IRES2 RNA lipid nanoparticles results in SVV replication in neuroblastoma tumors in vivo.

[0394] Example 14: Generation of neutralizing rabbit polyclonal antibodies against SVV Rabbit polyclonal antibodies were generated by immunizing rabbits with SVV virions, and the presence of anti-SVV antibodies in the sera of immunized rabbits was confirmed by ELISA (data not shown).

[0395] To determine whether anti-SVV antibodies could inhibit cell lysis, anti-SVV antibodies were administered to SVV virus (1 × 10 6 TCID50 / mL) and serial dilutions (1:2) were incubated on H446 cells. The lytic activity of H446 cells was calculated by CellTiter-Glo®. Figure 16A shows that SVV is neutralized by rabbit polyclonal antibodies at dilutions up to 1:320.

[0396] To determine the effectiveness of the 1:100 dilution of rabbit anti-SVV polyclonal antibody, different concentrations of SVV virus and diluted SVV antibody (1:100) were incubated on H446 cells. 2 ~10 7 All doses tested ranging from TCID50 / mL of SVV virus were neutralized by a 1:100 dilution of anti-SVV antibody. Groups 1, 2, and 3 are biological replicates of antibody dilutions.

[0397] Example 15: SVV-RNA lipid nanoparticles exhibit antitumor activity in the presence of neutralizing serum SVV RNA-lipid nanoparticles were tested in vivo in the presence of SVV-neutralizing antibodies.

[0398] Generation and testing of anti-SVV polyclonal antibodies is described in Example 14. Production, formulation, and analysis of SVV RNA-lipid nanoparticles is described in Example 2 and Table 18 below. [Table 18]

[0399] The ability of anti-SVV antibodies to inhibit tumor cell lysis induced by SVV RNA lipid nanoparticles was evaluated using the H1299 xenograft model, further described in Example 4. Briefly, nude mice bearing H1299 tumors (n=8 mice / group) were administered 100 μL of SVV-RNA lipid nanoparticles (formulation no. 80139-1.C) or SVV virions intravenously and injected intraperitoneally with either naive rabbit serum (negative control) or anti-SVV polyclonal antibodies. Tumor-bearing mice received two doses of antibody on days 0 and 7, and two doses of SVV virions or SVV RNA lipid nanoparticles on days 1 and 8 of the study. Tumor volumes were measured three times a week using electronic calipers. Treatment groups are shown in Table 19 below. [Table 19]

[0400] As shown in FIG. 17, SVV virion-treated mice immunized with naive rabbit serum showed significant inhibition of tumor growth (2-way ANOVA, Tukey's multiple comparison test, ****p<0.0001). In contrast, administration of SVV neutralizing antibodies to SVV virion-treated mice completely blocked the antitumor activity of SVV. Administration of SVV neutralizing antibodies (or naive rabbit serum) to mice treated with SVV RNA lipid nanoparticles did not affect the antitumor activity of SVV RNA lipid nanoparticles. SVV RNA lipid nanoparticle treatment significantly inhibited tumor growth in mice treated with SVV neutralizing serum (2-way ANOVA, Tukey's multiple comparison test, ****p<0.0001). Thus, unlike SVV virions, the antitumor activity of SVV RNA lipid nanoparticles is not affected by the presence of neutralizing antibodies in the circulation.

[0401] Example 16: In vivo efficacy of CVA21-encoding RNA lipid nanoparticles in melanoma Experiments were conducted to determine the ability of lipid nanoparticles containing RNA molecules encoding CVA21 to produce infectious virus in vivo and inhibit melanoma tumor growth. The production, formulation, and analysis of CVA21 RNA lipid nanoparticles are described in Example 2 and Table 20 below. [Table 20]

[0402] The ability of CVA21 RNA-lipid nanoparticles to inhibit tumor growth was evaluated using the SK-MEL28 xenograft model. Briefly, SK-MEL28 cells (1×10 in a 1:1 mixture of serum-free PBS and Matrigel®) were cultured in a 5% COC medium. 6 100 cells / 0.1 mL) were inoculated subcutaneously into the right flank of 8-week-old female athymic nude mice (Charles River Laboratories). The median tumor size was approximately 150 mm. 3 (120~180mm 3When tumor volume reached 100 μg / kg / day (range), mice were intravenously administered either RNA encoding CVA21 formulated in PBS or Lipoafectime RNAiMAx (1 μg) or RNA lipid nanoparticles encoding CVA21 (formulation no. 70032-6C, 5 μg). Mice received intratumoral treatment on days 1 and 5, or intravenous treatment on days 1, 6, 11, and 16. Tumor volumes were measured three times a week using electronic calipers.

[0403] As shown in Figure 18, intravenous treatment with LNPs containing CVA21 RNA molecules or intratumoral treatment with CVA21-RNA molecules formulated with lipofectamine prevented tumor growth in tumor-bearing mice compared to mice treated with PBS (2-way ANOVA, p<0.0.001). Taken together, these results suggest that lipid nanoparticles containing CVA21 RNA molecules are an effective therapeutic strategy for the treatment of melanoma.

[0404] Example 17: Strategy for the generation of discrete 3' ends of SVV As noted above, the synthetic genomes described herein require separate 3' and 5' ends that are natural to the virus in order to produce replicable and infectious viruses from the synthetic genomes. The RNA transcripts produced in vitro by T7 RNA polymerase are mammalian 5' and 3' UTRs and therefore do not contain the separate native ends necessary for the production of infectious ssRNA viruses.

[0405] To generate the separate 3' ends required for infectious SVV, a strategy was used that uses 3' restriction enzyme recognition sequences. A SapI restriction recognition sequence was inserted at the 3' end of the DNA template. SapI cleaves 5' of its recognition site to generate a polythymidine run of the appropriate length, generating separate viral polyadenylation sites that are native to the virus. This process is shown in Figure 19.

[0406] Example 18: RNase H strategy for the generation of distinct 5' ends of SVV An RNAseH strategy was used to generate separate 5' ends that are native to SVV. T7 RNA polymerase requires a guanosine residue at the 5' end. However, the 5' end of SVV begins with a uridine residue. Therefore, the T7 leader must be removed to generate the authentic ends of the virus. A diagram of the in vitro transcription (IVT) and 5' leader processing approach is shown in Figure 20. The IVT template is shown at the top and the resulting RNA transcript is shown in the middle. This SVV+ssRNA transcript is then annealed to a complementary dsDNA oligo (dashed box) and the portion is hydrolyzed with RNaseH. The final viral ssRNA product with the correct 5' end is shown at the bottom.

[0407] Correct processing of RNaseH engineered transcripts was assessed by primer extension analysis. RNA transcripts were either treated with RNaseH or left undigested. Complementary fluorescent primers were then added and annealed to the digested and undigested samples, then extended by Superscript IV reverse transcriptase. Products were then resolved on a TBE UREA acrylamide gel. The expected bands were as follows: undigested > 150bp and digested = 100bp. As shown in Figure 21, this strategy results in the correct processing of approximately 90% of the RNA, as indicated by the increase in digested bands in the presence of RNaseH.

[0408] This strategy, in combination with the 3' restriction enzyme strategy described in Example 19, produces a final synthetic SVV genome with separate 5' and 3' ends required for the production of infectious SVV.

[0409] Example 19: Ribozyme strategy for the generation of distinct 5' ends of SVV A ribozyme strategy was used to generate distinct 5' ends that are native to SVV. A schematic of this approach is shown in Figure 22, which shows the design of a ribozyme that cleaves at the 5' end of a picornavirus. The two ribozymes depicted are the hammerhead and pistol ribozymes, although several other ribozymes can be adapted to specifically cleave in this context.

[0410] Modifications of hammerhead and pistol ribozymes for the implementation of this strategy are shown in Figures 23 and 24, respectively. A structural model of a minimal hammerhead ribozyme (HHR) that anneals and cleaves the 5' end of SVV is shown in Figure 23A (this ribozyme cleaves the 5' end at the site indicated by the arrow). A structural model of a hammerhead ribozyme with stabilized stem I for cleavage of the SVV 5' end (STBL) is shown in Figure 23B (this ribozyme cleaves the 5' end at the site indicated by the arrow). Figure 24A shows a schematic of the pistol ribozyme characteristics found in the wild (pistol WT). Figure 24B shows the pistol ribozyme from P. polymyxa modeled by mFOLD with a tetraloop added to fuse the P3 strand. The nucleic acids in the dashed box were mutated to preserve the ribozyme folding in the context of the viral sequence. The WT "GUC" sequence shown in the dashed box was mutated to "UCA" to generate Pistol 1, and the "GUC" sequence was mutated to "TTA" to generate Pistol 2.

[0411] The ability of each of the four ribozymes (HHR, STBL, Pistol 1, and Pistol 2) to mediate cleavage during the IVT process was evaluated. The IVT template was linearized with HpaI to obtain a 150 nt run-off in the uncleaved case and two cleavage fragments of approximately 90 nt and approximately 60 nt in the ribozyme cleavage cases to obtain a readout of the ribozyme efficiency after the IVT process. As shown in Figure 25, three bands were present in all reactions with the ribozyme constructs. The two hammerhead ribozymes cleave with approximately 40-60% efficiency (STBL-lane 3 and HHR-lane 4). The Pistol 1 ribozyme in lane 5 had no visible uncleaved product on the gel. The Pistol 2 ribozyme in lane 6 visualized approximately 5% uncleaved product on the gel. Similar results were obtained using primer extension analysis (Figure 26). Primer extension products were resolved on a TBE UREA acrylamide gel. Expected bands were undigested ≧150 bp (see reference band of SVV-Neg in lane 7 at 150 bp) and digested = 80 bp. Pistol 1 results in complete cleavage evidenced by the absence of an upper band in lane 10.

[0412] These results indicate that all four of the ribozymes are able to mediate cleavage of the IVT transcript, however, the Pistol1 and Pistol2 ribozymes are more efficient, with Pistol1 being the most efficient, mediating complete cleavage during the IVT process.

[0413] Example 20: In vitro function of 5' ribozyme and 3' restriction enzyme engineered SVV genomes In vitro assays were performed to assess the functionality of SVV genomes engineered with a 5' ribozyme sequence and a 3' SapI restriction site. The following IVT templates were used to generate synthetic SVV genomes: (a) 5' HHR sequence and 3' SapI recognition sequence (b) 5' Pistol1 sequence and 3' SapI recognition sequence

[0414] H1299 cells were transfected with 1ug of IVT-produced RNA using Lipofectamine RNAiMax (Invitrogen). Total RNA was extracted from NCI-H1299 cells at 12h, 24h, and 36h using 250uL of QIAzol reagent from Qiagen. cDNA was produced from this RNA and analyzed with a minus-strand specific Taqman assay. NCI-H1299 cells were transfected with a fixed amount of the indicated IVT-produced RNA. Absolute qRT-PCR was performed on cDNA produced from this RNA over time. The early kinetics of SVV kickoff from H1299 cells is greatly enhanced in the Pistol1-SapI construct (Figure 27).

[0415] Example 21: In vivo efficacy of Pistol / SapI SVV RNA-lipid nanoparticles against tumor growth Experiments were performed to determine whether lipid nanoparticles containing SVV-Pistol / SapI RNA molecules could inhibit tumor growth in vivo.

[0416] The production, formulation, and analysis of SVV RNA-lipid nanoparticles is described in Example 2 and Table 21 below. [Table 21]

[0417] The ability of SVV-HHR-HDV and SVV-Pistol / SapI lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, which is further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were injected subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3When tumor volume reached 100 mg / kg, mice were intravenously administered lipid nanoparticles containing 0.2 mg / kg of SVV-HHR / HDV (formulation no. 80130-1.C) or SVV-Pistol / SapI (formulation no. 80130-3.C) RNA molecules (day 1). Subsequent doses of PBS or lipid nanoparticles were administered on day 8 of the study. Tumor volumes were measured 3 times a week using electronic calipers.

[0418] As shown in Figure 28, mice treated with SVV-HHR-HDV RNA or SVV-Pistol / SapI RNA lipid nanoparticles significantly inhibited tumor growth compared to mice treated with PBS (2-way ANOVA, Tukey's multiple comparison test, ****p<0.0001). Furthermore, treatment with SVV-Pistol / SapI RNA lipid nanoparticles was more effective in inhibiting tumor growth compared to SVV-HHR RNA lipid nanoparticles (2-way ANOVA, Tukey's multiple comparison test, ##p<0.01).

[0419] Example 22: In vitro synthesis of SVV-RNA with modified ribonucleotides Experiments were performed to evaluate the possibility of synthesizing SVV-RNA in vitro with modified ribonucleotides to enhance RNA stability. In vitro synthesis of SVV positive-sense RNA encoding mCherry (a marker for gene expression and viral replication, SVV-mCherry) was performed without or with modified ribonucleotides (Figure 29A). In vitro synthesized RNA was formulated in RNAiMax (Invitrogen, Thermo Fisher, Waltham, MA) and transfected into NCI-H1299 human cancer lung cells for 4 hours, after which the cells were washed and fresh medium was added for 72 hours. The presence of the red fluorescent protein mCherry (shown as lighter shading in Figure 29B) was used as a proxy for viral replication.

[0420] As shown in Figure 29A, the synthesis of SVV-mCherry-RNA with Ψ-UTP or 5-m-CTP was efficient. When both modified ribonucleotides were combined, no RNA was produced. This indicated that the presence of multiple modified ribonucleotides did not support IVT of SVV-RNA. Transfection of SVV-Ψ-UTP RNA or SVV-5-m-CTP RNA did not show viral replication (Figure 29B). The secondary structure of viral RNA is key to support viral replication, and in the case of SVV, it is the use of modified ribonucleotides that can change the natural secondary structure of RNA and prevent viral replication.

[0421] Example 23: Expression of payload molecules from the SVV genome Experiments were performed to evaluate whether polynucleotides encoding payload molecules could be expressed from the SVV viral genome. Expression cassettes for each of mCherry, nanoluciferase, CXCL10, IL-12, GM-CSF, and FAP-CD3 BiTE were inserted into a plasmid encoding the SVV genome. H1299 cells were transfected with 0.015 pmol of the plasmid, and the supernatant was harvested and filtered to collect viral particles. The filtered supernatant was transferred to H446 cultures and infectivity was assessed. As shown in Figure 30, each of the payload engineered viruses was able to infect H446 cells, albeit with varying degrees of efficacy. The IC50 for each construct is provided in Table 22 below. These data indicate that SVV can be engineered to express various payload molecules to enhance the therapeutic efficacy of the virus. [Table 22]

[0422] Example 24: In vivo efficacy of SVV encoding payload RNA-lipid nanoparticles on tumor growth and payload expression in tumor tissue Experiments were performed to determine whether lipid nanoparticles containing SVV payload RNA could inhibit tumor growth in vitro and to evaluate payload expression in tumor tissue.

[0423] The production, formulation, and analysis of SVV-Neg, SVV-WT, and SVV-IL-36γ RNA (SEQ ID NO: 11) lipid nanoparticles are described in Example 2 and Tables 23 and 24 below. [Table 23] [Table 24]

[0424] The ability of SVV-WT+SVV-Neg and SVV-WT+SVV-IL-36γ lipid nanoparticles to inhibit tumor growth was evaluated using the H1299 xenograft model, as further described in Example 4. Briefly, 5×10 6 NCI-H1299 cells were injected subcutaneously into the right flank of hypothymic nude mice. Median tumor size was approximately 150 mm. 3 When tumor volume reached 100 mg / kg, mice were intravenously administered lipid nanoparticles containing 0.2 mg / kg of SVV-WT+SVV-Neg (formulation no. 80116-3.C+80116-4.C mixture (1:1 ratio)) or SVV-WT+SVV-IL-36γ (formulation no. 80116-4.C+80116-5.C mixture (1:1 ratio)) RNA molecules (day 1). Subsequent doses of PBS or lipid nanoparticles were administered on day 8 of the study. Tumor volumes were measured 3 times a week using electronic calipers. On day 10, the study was terminated and tumors were collected for payload expression analysis.

[0425] As shown in Figure 31A, mice treated with SVV-WT+SVV-Neg or SVV-WT+SVV-IL-36γ RNA lipid nanoparticles showed significantly lower tumor burden compared to mice treated with PBS (2-way ANOVA, Tukey's multiple comparison test, ****p<0.0001). These results indicate that lipid nanoparticles containing SVV-WT+SVV-IL-36γ RNA molecules exhibit antitumor activity in vivo.

[0426] Tumor tissues collected at the end of the study were processed to generate tumor lysates. IL36γ levels were determined by Elisa (R&D System, DY2320-05). As shown in Figure 31B, human IL-36γ was detected in mice treated with SVV-WT+SVV-IL36γ RNA lipid nanoparticles. These results indicate that lipid nanoparticles containing SVV-IL-36γ RNA molecules support the expression of the transgene encoded by the viral genome in tumor tissue.

[0427] Example 25: Optimization of RNA molecules encoding Coxsackie virus Experiments were performed to evaluate the ability to produce infectious Coxsackie virus A21 (CVA21) from recombinant RNA molecules. Briefly, RNA polynucleotides containing the CVA21 viral genome were generated by T7 transcription in vitro based on the previously described CVA21 genome sequence (Newcombe et al., Cellular See receptor interactions of C-cluster human group A coxsackieviruses Journal of General Virology (2003), 84, 3041-3050. GenBank accession number AF465515). SK-MEL-28 cells were transfected with 1 μg of CVA21 RNA construct with Lipofectamine RNAiMax for 4 hours, at which time wells were washed and complete medium was added to each well. After 48 hours, supernatants were removed from SK-MEL-28 cultures and cells were stained with crystal violet to assess viral infectivity. As shown in FIG. 32A (left panel), RNA molecules containing the Newcombe CVA21 sequence (CVA21 WT) did not produce active lytic virus (as indicated by crystal violet staining of unlysed SK-MEL-28 cells).

[0428] Surprisingly, modifications to the 5'UTR were required for the production of infectious CVA21 from recombinant RNA molecules. As shown in Figure 32A (right panel), incorporation of the 5'UTR sequence described by Brown et al. (Journal of Virology, (2003) 77:16, p. 8973-8984. GenBank Accession No. AF546702) into the CVA21 genome sequence described by Newcombe (CVA21-Brown) resulted in the production of infectious CVA21 virus and viral cell lysis, as indicated by the lack of crystal violet staining across multiple independent clones. Supernatants from SK-MEL-28 cells transfected with two different CVA21-Brown clones were collected after 72 hours, syringe filtered through 0.45 μM filters, and serially diluted into fresh SK-MEL-28 cells. After 48 hours, supernatants were removed from the SK-MEL-28 cultures and cells were stained with crystal violet to assess viral infectivity. As shown in Figure 32B, RNA molecules encoding CVA21 containing the Brown 5'UTR sequence (UTR sequence - sequence number 26, modified CVA21 sequence - sequence number 27) resulted in the production and release of infectious CVA21 into the supernatant of transfected cells, as demonstrated by the ability of only the supernatant to mediate cell lysis.

[0429] Incorporation by Reference All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entirety for all purposes. However, mention of any references, articles, publications, patents, patent publications, and patent applications cited herein is not, and should not be taken as, any form of acknowledgment or suggestion that they constitute valid prior art or form part of the general knowledge in any country in the world.

[0430] While preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Those skilled in the art will envision numerous variations, changes, and substitutions without departing from the present disclosure. It is understood that various alternatives to the embodiments of the present disclosure described herein may be employed in the practice of the present disclosure. The following claims define the scope of the present disclosure, and it is intended that methods and structures falling within the scope of these claims, and their equivalents, be covered thereby. The present invention provides, for example, the following items. (Item 1) Lipid nanoparticles (LNPs) containing a synthetic RNA viral genome encoding an oncolytic virus. (Item 2) The LNP of item 1, wherein the oncolytic virus is a single-stranded RNA (ssRNA) virus. (Item 3) The LNP of item 1, wherein the oncolytic virus is a positive-sense ((+)-sense) ssRNA virus. (Item 4) The LNP of item 3, wherein the (+)-sense ssRNA virus is selected from those listed in Table 1. (Item 5) The LNP of item 3, wherein the (+)-sense ssRNA virus is a picornavirus. (Item 6) 6. The LNP of item 5, wherein the picornavirus is Seneca Valley virus (SVV) or Coxsackie virus. (Item 7) The LNP of item 6, wherein the SVV is an SVV-A selected from wild-type SVV-A (sequence number 1), an S177A-SVVA mutant (sequence number 2), an SVV-IR2 mutant (sequence number 3), and an SVV-IR2-S177A mutant (sequence number 4). (Item 8) 7. The LNP of item 6, wherein the Coxsackie virus is selected from CVB3, CVA21, and CVA9. (Item 9) 7. The LNP of item 6, wherein the Coxsackie virus is a modified CVA21 virus comprising SEQ ID NO:27. (Item 10) 10. The LNP of any one of items 1 to 9, wherein delivery of said LNP to a cell results in the production of viral particles by said cell, said viral particles being infectious and lytic. (Item 11) 11. The LNP of any one of items 1 to 10, wherein the synthetic RNA virus genome further comprises a heterologous polynucleotide encoding an exogenous payload protein. (Item 12) 11. The LNP of any one of items 1 to 10, further comprising a recombinant RNA molecule encoding an exogenous payload protein. (Item 13) 13. The LNP according to item 11 or 12, wherein the exogenous payload protein is a fluorescent protein, an enzyme protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand of a cell surface receptor. (Item 14) 14. The LNP of item 13, wherein the cytokine is selected from IL-12, GM-CSF, IL-18, IL-2, and IL-36γ. (Item 15) 14. The LNP of item 13, wherein the ligand of the cell surface receptor is Flt3 ligand or TNFSF14. (Item 16) 14. The LNP of item 13, wherein the chemokine is selected from CXCL10, CCL4, CCL21, and CCL5. (Item 17) The LNP according to item 13, wherein the antigen-binding molecule is capable of binding to and inhibiting an immune checkpoint receptor. (Item 18) 18. The LNP of item 17, wherein the immune checkpoint receptor is PD-1. (Item 19) The LNP according to item 13, wherein the antigen-binding molecule is capable of binding to a tumor antigen. (Item 20) 20. The LNP of item 19, wherein the antigen-binding molecule is a bispecific T cell-associated molecule (BiTE) or a bispecific light T cell-associated molecule (LiTE). (Item 21) 21. The LNP of item 19 or 20, wherein the tumor antigen is DLL3 or EpCAM. (Item 22) 19. The LNP according to any one of items 1 to 18, wherein the synthetic RNA viral genome and / or the recombinant RNA molecule comprises a microRNA (miRNA) target sequence (miR-TS) cassette, and the miR-TS cassette comprises one or more miRNA target sequences. (Item 23) 23. The LNP of item 22, wherein the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126. (Item 24) 24. The LNP of item 23, wherein the miR-TS cassette comprises one or more copies of a miR-124 target sequence, one or more copies of a miR-1 target sequence, and one or more copies of a miR-143 target sequence. (Item 25) 24. The LNP of item 23, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence. (Item 26) 24. The LNP of item 23, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence. (Item 27) 24. The LNP of item 23, wherein the miR-TS cassette comprises one or more copies of a miR-217 target sequence, one or more copies of a miR-137 target sequence, and one or more copies of a miR-126 target sequence. (Item 28) 28. The LNP according to any one of items 1 to 27, wherein the LNP comprises a cationic lipid, one or more helper lipids, and a phospholipid-polymer complex. (Item 29) 29. The LNP of item 28, wherein the cationic lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly named SS-18 / 4PE-13), COATSOME® SS-EC (formerly named SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). (Item 30) 30. The LNP of item 28 or 29, wherein the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol. (Item 31) 29. The LNP of claim 28, wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). (Item 32) 31. The LNP according to any one of claims 28 to 30, wherein the phospholipid-polymer complex is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol (DPG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine). (Item 33) 33. The LNP according to any one of items 28 to 32, wherein the phospholipid-polymer complex is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PEG5K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K). (Item 34) 29. The LNP of item 28, wherein the cationic lipid comprises COATSOME® SS-OC, the one or more helper lipids comprise cholesterol (Chol) and DSPC, and the phospholipid-polymer complex comprises DPG-PEG2000. (Item 35) 35. The LNP according to item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%. (Item 36) 35. The LNP according to item 34, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%. (Item 37) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5. (Item 38) 35. The LNP according to item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 39) 35. The LNP according to item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 40) 35. The LNP according to item 34, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. (Item 41) 35. The LNP according to item 34, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%. (Item 42) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 49:11:38.5:1.5. (Item 43) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=45%-65%, B=5%-20%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 44) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=50%-60%, B=5%-15%, C=30%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 45) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=55%-60%, B=5%-15%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. (Item 46) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about A:B:C:D, where A=55%-60%, B=5%-10%, C=30%-35%, and D=1%-2%, and A+B+C+D=100%. (Item 47) 35. The LNP of item 34, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 58:7:33.5:1.5. (Item 48) 43. The LNP of any one of items 1 to 42, wherein the LNP comprises a lipid formulation selected from Table 5. (Item 49) 49. The LNP of any one of items 1 to 48, wherein hyaluronan is conjugated to the surface of the LNP. (Item 50) A therapeutic composition comprising a plurality of lipid nanoparticles according to any one of items 1 to 49. (Item 51) 51. The therapeutic composition according to item 50, wherein the plurality of LNPs have an average size of about 50 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm. (Item 52) 51. The therapeutic composition of item 50, wherein the plurality of LNPs have an average size of about 50 nm to about 120 nm. (Item 53) 51. The therapeutic composition of claim 50, wherein the LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm. (Item 54) 51. The therapeutic composition of claim 50, wherein the LNPs have an average size of about 100 nm. (Item 55) 55. The therapeutic composition of any one of items 50 to 54, wherein the plurality of LNPs have an average zeta potential between about 40 mV to about -40 mV, about 20 mV to about -20 mV, about 10 mV to about -10 mV, about 5 mV to about -5 mV, or about 20 mV to about -40 mV. (Item 56) 55. The therapeutic composition of any one of items 50-54, wherein the plurality of LNPs have an average zeta potential of less than about -20 mV, less than about -30 mV, less than about -35 mV, or less than about -40 mV. (Item 57) 57. The therapeutic composition of item 56, wherein the plurality of LNPs have an average zeta potential between about -50 mV to about -20 mV, about -40 mV to about -20 mV, or about -30 mV to about -20 mV. (Item 58) 58. The therapeutic composition of claim 56 or 57, wherein the plurality of LNPs have an average zeta potential of about -30mV, about -31mV, about -32mV, about -33mV, about -34mV, about -35mV, about -36mV, about -37mV, about -38mV, about -39mV, or about -40mV. (Item 59) 59. The therapeutic composition according to any one of items 50 to 58, wherein upon administration of the therapeutic composition to a subject, the recombinant RNA polynucleotide is delivered to a target cell of the subject, and the recombinant RNA polynucleotide produces an infectious oncolytic virus capable of lysing the target cell of the subject. (Item 60) 60. The therapeutic composition of claim 59, wherein the composition is formulated for intravenous or intratumoral delivery. (Item 61) 60. The therapeutic composition of claim 59, wherein the target cell is a cancerous cell. (Item 62) 62. A method for inhibiting the growth of a cancerous tumor in a subject in need thereof, comprising administering to a subject in need thereof a therapeutic composition according to any one of items 50 to 61, wherein administration of the composition inhibits the growth of the tumor. (Item 63) 63. The method of claim 62, wherein the administration is intratumoral or intravenous. (Item 64) 64. The method of item 62 or 63, wherein the cancer is lung cancer, liver cancer, prostate cancer, bladder cancer, pancreatic cancer, gastric cancer, breast cancer, neuroblastoma, rhabdomyosarcoma, medulloblastoma, or melanoma. (Item 65) 65. The method according to any one of items 62 to 64, wherein the cancer is a neuroendocrine cancer. (Item 66) A recombinant RNA molecule comprising a synthetic RNA viral genome encoding an oncolytic virus. (Item 67) 67. The recombinant RNA molecule of item 66, wherein the encoded oncolytic virus is a single-stranded RNA (ssRNA) virus. (Item 68) 68. The recombinant RNA molecule according to item 67, wherein the ssRNA virus is a positive-sense ((+)-sense) or negative-sense ((-)-sense) ssRNA virus. (Item 69) 70. The recombinant RNA molecule according to item 68, wherein the (+)-sense ssRNA virus is a picornavirus. (Item 70) 70. The recombinant RNA molecule of item 69, wherein the picornavirus is Seneca Valley virus (SVV) or Coxsackie virus. (Item 71) The recombinant RNA molecule of item 70, wherein the SVV is an SVV-A selected from wild-type SVV-A (sequence number 1), an S177A-SVVA mutant (sequence number 2), an SVV-IR2 mutant (sequence number 3), or an SVV-IR2-S177A mutant (sequence number 4). (Item 72) 71. The recombinant RNA molecule of item 70, wherein the Coxsackie virus is selected from CVB3, CVA21, and CVA9. (Item 73) 71. The recombinant RNA molecule of item 70, wherein the Coxsackie virus is a modified CVA21 virus comprising SEQ ID NO:27. (Item 74) 74. The recombinant RNA molecule of any one of items 66 to 73, further comprising a microRNA (miRNA) target sequence (miR-TS) cassette inserted into a polynucleotide sequence encoding the oncolytic virus, wherein the miR-TS cassette comprises one or more miRNA target sequences, and expression of one or more of the corresponding miRNAs in a cell inhibits replication of the encoded virus in the cell. (Item 75) 75. The recombinant RNA molecule according to item 74, wherein the one or more miRNAs are selected from miR-124, miR-1, miR-143, miR-128, miR-219, miR-219a, miR-122, miR-204, miR-217, miR-137, and miR-126. (Item 76) 76. The recombinant RNA molecule of item 75, wherein the miR-TS cassette comprises one or more copies of a miR-124 target sequence, one or more copies of a miR-1 target sequence, and one or more copies of a miR-143 target sequence. (Item 77) 76. The recombinant RNA molecule of item 75, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-219a target sequence, and one or more copies of a miR-122 target sequence. (Item 78) 76. The recombinant RNA molecule of item 75, wherein the miR-TS cassette comprises one or more copies of a miR-128 target sequence, one or more copies of a miR-204 target sequence, and one or more copies of a miR-219 target sequence. (Item 79) 76. The recombinant RNA molecule of item 75, wherein the miR-TS cassette comprises one or more copies of a miR-217 target sequence, one or more copies of a miR-137 target sequence, and one or more copies of a miR-126 target sequence. (Item 80) 80. The recombinant RNA molecule according to any one of items 66 to 79, wherein the recombinant RNA molecule, when introduced into a cell by a non-viral delivery vehicle, is capable of producing a replication-competent oncolytic virus. (Item 81) 81. The recombinant RNA molecule of item 80, wherein the cell is a mammalian cell. (Item 82) 82. The recombinant RNA molecule of item 81, wherein the cell is a mammalian cell present in a mammalian subject. (Item 83) 83. The recombinant RNA molecule according to any one of items 66 to 82, wherein the replication-competent virus is selected from the group consisting of Coxsackie virus, poliovirus, Seneca valley virus, lassa virus, murine leukemia virus, influenza A virus, influenza B virus, Newcastle disease virus, measles virus, sindbis virus, and maraba virus. (Item 84) 75. The recombinant RNA molecule of item 74, wherein the one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more essential viral genes. (Item 85) 85. The recombinant RNA molecule of item 84, wherein the one or more miR-TS cassettes are integrated into the 5' untranslated region (UTR) or 3' UTR of one or more non-essential genes. (Item 86) 86. The recombinant RNA molecule according to any of items 66 to 85, wherein the recombinant RNA molecule is inserted into a nucleic acid vector. (Item 87) 142. The recombinant RNA molecule of claim 141, wherein the nucleic acid vector is a replicon. (Item 88) 88. The recombinant RNA molecule according to items 66 to 87, wherein the synthetic RNA viral genome further comprises a heterologous polynucleotide encoding an exogenous payload protein. (Item 89) 89. The recombinant RNA molecule according to item 88, wherein the exogenous payload protein is a fluorescent protein, an enzymatic protein, a cytokine, a chemokine, an antigen-binding molecule capable of binding to a cell surface receptor, or a ligand capable of binding to a cell surface receptor. (Item 90) 90. The recombinant RNA molecule of item 89, wherein the cytokine is selected from IL-12, GM-CSF, IL-18, IL-2, and IL-36γ. (Item 91) 90. The recombinant RNA molecule of item 89, wherein the ligand of the cell surface receptor is Flt3 ligand or TNFSF14. (Item 92) 90. The recombinant RNA molecule according to item 89, wherein the chemokine is selected from CXCL10, CCL4, CCL21, and CCL5. (Item 93) 90. The recombinant RNA molecule of item 89, wherein the antigen binding molecule is capable of binding to and inhibiting an immune checkpoint receptor. (Item 94) 94. The recombinant RNA molecule of item 93, wherein the immune checkpoint receptor is PD-1. (Item 95) 90. The recombinant RNA molecule of item 89, wherein the antigen-binding molecule is capable of binding to a tumor antigen. (Item 96) 96. The recombinant RNA molecule of item 95, wherein the antigen-binding molecule is a bispecific T cell-associated molecule (BiTE) or a bispecific light T cell-associated molecule (LiTE). (Item 97) 97. The recombinant RNA molecule according to item 95 or 96, wherein the tumor antigen is DLL3 or EpCAM. (Item 98) 11. A recombinant DNA molecule comprising, from 5' to 3', a promoter sequence, a 5' junction cleavage sequence, a polynucleotide sequence encoding the recombinant RNA molecule according to any one of items 66 to 97, and a 3' junction cleavage sequence. (Item 99) 99. The recombinant DNA molecule of item 98, wherein the promoter sequence is a T7 promoter sequence. (Item 100) 100. The recombinant DNA molecule according to item 98 or 99, wherein the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a ribozyme sequence. (Item 101) 101. The recombinant DNA molecule of claim 100, wherein the 5' ribozyme sequence is a hammerhead ribozyme sequence and the 3' ribozyme sequence is a hepatitis delta virus ribozyme sequence. (Item 102) 100. The recombinant DNA molecule according to item 98 or 99, wherein the 5' junction cleavage sequence is a ribozyme sequence and the 3' junction cleavage sequence is a restriction enzyme recognition sequence. (Item 103) 103. The recombinant DNA molecule of claim 102, wherein the 5' ribozyme sequence is a hammerhead ribozyme sequence, a pistol ribozyme sequence, or a modified pistol ribozyme sequence. (Item 104) 104. The recombinant DNA molecule according to item 102 or 103, wherein the 3' restriction enzyme recognition sequence is a type IIS restriction enzyme recognition sequence. (Item 105) 105. The recombinant DNA molecule according to item 104, wherein the type IIS recognition sequence is a SapI recognition sequence. (Item 106) 100. The recombinant DNA molecule according to item 98 or 99, wherein the 5' junction cleavage sequence is an RNAseH primer binding sequence and the 3' junction cleavage sequence is a restriction enzyme recognition sequence. (Item 107) 107. A method for producing a recombinant RNA molecule according to any one of items 66 to 97, comprising in vitro transcription of a DNA molecule according to any one of items 98 to 106 and purification of the resulting recombinant RNA molecule. (Item 108) 108. The method of claim 107, wherein the recombinant RNA molecule comprises 5' and 3' ends that are native to the oncolytic virus encoded by the synthetic RNA viral genome. (Item 109) 8. A composition suitable for administration to a mammalian subject, comprising an effective amount of a recombinant RNA molecule according to any one of items 66 to 97, and a carrier. (Item 110) 8. A particle comprising a recombinant RNA molecule according to any one of items 66 to 97. (Item 111) Item 111. The particle according to item 110, wherein the particle is biodegradable. (Item 112) Item 112. The particle according to item 111, wherein the particle is selected from the group consisting of nanoparticles, exosomes, liposomes, and lipoplexes. (Item 113) 113. The particle according to item 112, wherein the exosomes are modified exosomes derived from intact exosomes or empty exosomes. (Item 114) 13. The particle according to claim 112, wherein the nanoparticle is a lipid nanoparticle (LNP) comprising a cationic lipid, one or more helper lipids, and a phospholipid-polymer complex. (Item 115) Item 115. The particle according to item 114, wherein the cationic lipid is selected from DLinDMA, DLin-KC2-DMA, DLin-MC3-DMA (MC3), COATSOME® SS-LC (formerly named: SS-18 / 4PE-13), COATSOME® SS-EC (formerly named: SS-33 / 4PE-15), COATSOME® SS-OC, COATSOME® SS-OP, di((Z)-non-2-en-1-yl) 9-((4-dimethylamino)butanoyl)oxy)heptadecanedioate (L-319), or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP). (Item 116) 116. The particle according to claim 114 or 115, wherein the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol. (Item 117) Item 115. The particle according to item 114, wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). (Item 118) 117. The particle according to any one of claims 114 to 116, wherein the phospholipid-polymer complex is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol (DPG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene (DSG-PEG), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine). (Item 119) Item 119. The particle according to any one of items 114 to 118, wherein the phospholipid-polymer complex is selected from 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-5000] (DSPE-PEG5K), 1,2-dipalmitoyl-rac-glycerol methoxypolyethylene glycol-2000 (DPG-PEG2K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DSG-PEG5K), 1,2-distearoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DSG-PEG2K), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-5000 (DMG-PEG5K), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene-2000 (DMG-PEG2K). (Item 120) Item 115. The particle according to item 114, wherein the cationic lipid comprises COATSOME® SS-OC, the one or more helper lipids comprise cholesterol (Chol) and DSPC, and the phospholipid-polymer complex comprises DPG-PEG2000. (Item 121) Item 121. The particles according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=40%-60%, B=10%-25%, C=20%-30%, and D=0%-3%, and A+B+C+D=100%. (Item 122) Item 121. The particles according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=20%-25%, C=25%-30%, and D=0%-1%, and A+B+C+D=100%. (Item 123) 121. The particle according to item 120, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is about 49:22:28.5:0.5. (Item 124) Item 121. The particles according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=40%-60%, B=10%-30%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 125) Item 121. The particles according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=40%-60%, B=10%-30%, C=25%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 126) Item 121. The particles according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-55%, B=10%-20%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. (Item 127) Item 121. The particles according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are A:B:C:D, where A=45%-50%, B=10%-15%, C=35%-40%, and D=1%-2%, and A+B+C+D=100%. (Item 128) 121. The particle according to item 120, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 49:11:38.5:1.5. (Item 129) 121. The particle according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are about A:B:C:D, where A=45%-65%, B=5%-20%, C=20%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 130) 121. The particle according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are about A:B:C:D, where A=50%-60%, B=5%-15%, C=30%-45%, and D=0%-3%, and A+B+C+D=100%. (Item 131) 121. The particle according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are about A:B:C:D, where A=55%-60%, B=5%-15%, C=30%-40%, and D=1%-2%, and A+B+C+D=100%. (Item 132) 121. The particle according to item 120, wherein the ratios of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) are about A:B:C:D, where A=55%-60%, B=5%-10%, C=30%-35%, and D=1%-2%, and A+B+C+D=100%. (Item 133) 121. The particle according to item 120, wherein the ratio of SS-OC:DSPC:Chol:DPG-PEG2K (as a percentage of the total lipid content) is 58:7:33.5:1.5. (Item 134) 134. The particle according to any one of items 110 to 133, wherein the LNP comprises a lipid formulation selected from Table 5. (Item 135) Item 115. The particle according to item 114, wherein the cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the neutral lipid is 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). (Item 136) Item 114 or 135, the particle further comprising a phospholipid-polymer complex, said phospholipid-polymer complex being 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG-amine). (Item 137) 137. The particle according to any one of items 110 to 136, wherein hyaluronan is conjugated to the surface of the LNP. (Item 138) 137. The particle according to any one of items 110 to 136, further comprising a second recombinant RNA molecule encoding a payload molecule. (Item 139) 139. The particle of item 138, wherein the second recombinant RNA molecule is a replicon. (Item 140) A therapeutic composition comprising a plurality of lipid nanoparticles according to any one of items 114 to 139. (Item 141) Item 141. The therapeutic composition according to item 140, wherein the plurality of LNPs have an average size of about 50 nm to about 500 nm, about 150 nm to about 500 nm, about 200 nm to about 500 nm, about 300 nm to about 500 nm, about 350 nm to about 500 nm, about 400 nm to about 500 nm, about 425 nm to about 500 nm, about 450 nm to about 500 nm, or about 475 nm to about 500 nm. (Item 142) Item 141. The therapeutic composition of item 140, wherein the plurality of LNPs have an average size of about 50 nm to about 120 nm. (Item 143) 141. The therapeutic composition of claim 140, wherein the LNPs have an average size of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, or about 120 nm. (Item 144) Item 141. The therapeutic composition of item 140, wherein the plurality of LNPs have an average size of about 100 nm. (Item 145) 145. The therapeutic composition of any one of items 140 to 144, wherein the plurality of LNPs have an average zeta potential between about 20 mV to about -20 mV, about 10 mV to about -10 mV, about 5 mV to about -5 mV, or about 20 mV to about -40 mV. (Item 146) 145. The therapeutic composition of any one of items 140-144, wherein the plurality of LNPs have an average zeta potential of less than about -20 mV, less than about -30 mV, less than about -35 mV, or less than about -40 mV. (Item 147) Item 147. The therapeutic composition of item 146, wherein the plurality of LNPs have an average zeta potential between about -50 mV to about -20 mV, about -40 mV to about -20 mV, or about -30 mV to about -20 mV. (Item 148) 147. The therapeutic composition of claim 141 or 146, wherein the plurality of LNPs have an average zeta potential of about -30mV, about -31mV, about -32mV, about -33mV, about -34mV, about -35mV, about -36mV, about -37mV, about -38mV, about -39mV, or about -40mV. (Item 149) 149. The therapeutic composition of any one of items 140 to 148, wherein delivery of the composition to a subject delivers an encapsulated recombinant RNA molecule to a target cell, and the encapsulated recombinant RNA molecule produces an infectious virus capable of lysing the target cell. (Item 150) 150. The therapeutic composition of claim 149, wherein the composition is formulated for intravenous or intratumoral delivery. (Item 151) 151. The therapeutic composition of claim 150, wherein the target cell is a cancerous cell. (Item 152) 8. An inorganic particle comprising the recombinant polynucleotide according to any one of items 66 to 97. (Item 153) Item 153. The inorganic particle according to item 152, wherein the inorganic particle is selected from the group consisting of gold nanoparticles (GNPs), gold nanorods (GNRs), magnetic nanoparticles (MNPs), magnetic nanotubes (MNTs), carbon nanohorns (CNHs), carbon fullerenes, carbon nanotubes (CNTs), calcium phosphate nanoparticles (CPNPs), mesoporous silica nanoparticles (MSNs), silica nanotubes (SNTs), or star-shaped hollow silica nanoparticles (SHNPs). (Item 154) 151. The inorganic particle according to item 150, further comprising a second recombinant RNA molecule encoding a payload molecule. (Item 155) Item 155. The particle according to item 154, wherein the second recombinant RNA molecule is a replicon. (Item 156) 156. A composition comprising inorganic particles according to any one of items 152 to 155, wherein the average diameter of the particles is less than about 500 nm, is about 50 nm to 500 nm, is about 250 nm to about 500 nm, or is about 350 nm. (Item 157) 15. A method of killing a cancerous cell, comprising exposing said cancerous cell to a particle according to any one of items 1 to 49, 110 to 139, or 152 to 155, a recombinant RNA molecule according to any one of items 66 to 97, or a composition thereof, under conditions sufficient to intracellularly deliver said particle to said cancerous cell, wherein a replication-competent virus produced by said encapsulated polynucleotide results in killing of said cancerous cell. (Item 158) 158. The method of claim 157, wherein the replication-competent virus is not produced in a non-cancerous cell. (Item 159) 159. The method according to item 157 or 158, wherein the method is performed in vivo, in vitro, or ex vivo. (Item 160) 1. A method for treating cancer in a subject, comprising administering to a subject suffering from said cancer an effective amount of a particle according to any one of items 1 to 49, 110 to 139, or 152 to 155, a recombinant RNA particle according to any one of items 66 to 97, or a composition thereof. (Item 161) 161. The method of claim 160, wherein the particles or compositions thereof are administered intravenously, intranasally, as an inhalant, or injected directly into the tumor. (Item 162) 162. The method of claim 160 or 161, wherein the particles or compositions thereof are repeatedly administered to the subject. (Item 163) 163. The method according to any of items 160 to 162, wherein the subject is a mouse, a rat, a rabbit, a cat, a dog, a horse, a non-human primate, or a human. (Item 164) The method according to any one of items 160 to 163, wherein the cancer is selected from lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), sarcoma, neuroblastoma, neuroendocrine carcinoma, rhabdomyosarcoma, medulloblastoma, bladder cancer, and marginal zone lymphoma (MZL). (Item 165) Item 165. The method of item 164, wherein the lung cancer is small cell lung cancer or non-small cell lung cancer. (Item 166) Item 165. The method of item 164, wherein the liver cancer is hepatocellular carcinoma (HCC). (Item 167) 165. The method of claim 164, wherein the prostate cancer is a treatment-emerging neuroendocrine prostate cancer. (Item 168) 168. The method according to any of items 150 to 167, wherein the cancer is a neuroendocrine cancer.

Claims

[Claim 1] The invention described in the specification.